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In 2014 there were an estimated 37 million people living with HIV (PLHIV) 
globally, while over 39 million had died from AIDS over the nearly four decades 
of the epidemic (UNAIDS 2014a, UNAIDS 2015a). In 2011, to guide the 
expansion of global HIV response beyond the HIV-specific programmes of the 
past, the World Health Organization (WHO) developed the Global Health 
Sector Strategy on HIV/AIDS for 2011–2015, aiming at no new HIV infections, 
no AIDS-related deaths, and no discrimination (WHO 2011). 
Although effective response to HIV/AIDS is multidimensional, antiretroviral 
therapy (ART) is a fundamental element in tackling the disease in people infected 
with HIV. While first antiretroviral (ARV) drugs were developed already in the 
mid 1980s, it took another 10 years of intensive research to reach triple-
combination therapy (currently known as combined or highly active ART), 
leading to significant reductions in illness and death among PLHIV (receiving 
ART). It has been estimated that since 2000, when WHO and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) started setting global targets for 
ART access (among other measures), the rollout of the therapy has saved about 
7.8 million lives worldwide (Fauci & Marston 2015), and in 2015 an estimated 
15.8 million people of the approximately 37 million living with HIV in the 
world had access to ART (UNAIDS 2015a, UNAIDS 2015b).  
Combined ART, an effective (biomedical) intervention, is critical for the 
health and wellbeing of PLHIV, and furthermore significantly reduces the prob-
ability of transmitting the virus to others. Focus on preventing new infections 
has expanded from HIV-negative individuals to PLHIV to mitigate the spread 
of HIV to their sexual and injection-drug-use partners, and to infants born to 
HIV-infected mothers. It has been recognized that, from a public health per-
spective, it could be more efficient to fight the HIV epidemic when attempting 
to change behavior among the fewer HIV-positives than the many HIV-negatives 
(Kennedy et al. 2010, Mermin 2011, Lasry et al. 2012). While initially HIV 
prevention strategies for PLHIV only encompassed screening for behavioral 
risk factors and sexually transmitted infections, partner notification, prevention 
counseling and behavioral risk reduction interventions (CDC et al. 2003), the 
current much broader concept of ‘prevention with positives’ also includes bio-
medical prevention, the ‘treatment cascade’, the social and structural needs of 
people living with the virus, and advice for PLHIV wanting to have children 
(CDC et al. 2014).  
Globally, substantial progress has been made in impeding HIV, especially in 
the past 3–4 years and in areas where clear intervention targets have been set. 
However, in 2014 UNAIDS set new targets: 90% of people living with HIV 
should know their HIV status, 90% of people diagnosed with HIV should receive 
ART, and 90% of people on ART should have viral suppression. Modelling 
suggests that achieving these targets by 2020 would enable the world to end the 
HIV/AIDS epidemic by 2030 (UNAIDS 2014b, UNAIDS 2014c). In order to 
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attain the 90–90–90 targets, extensive efforts to expand the coverage and 
improve the quality of HIV prevention, diagnosis, treatment and care inter-
ventions should continue (WHO 2014a). Identification of gaps in connecting 
PLHIV to sustained and high quality HIV care would enable service providers 
and policymakers to enhance the system. The HIV/AIDS treatment cascade as a 
model to map the proportion of PLHIV who actually receive the full benefit of 
the medical care they need for HIV (including ART) was first described by 
Gardner and colleagues in 2011 (Gardner et al. 2011). Since its development, 
the cascade approach was immediatelty recognized worldwide and has since 
been applied in an escalating number of countries to assess the performance of 
national response to HIV (Helleberg et al. 2013, Pokrovskaya et al. 2014, 
Raymond et al. 2014, Levi et al. 2015, Medland et al. 2015).  
However, the number of people newly infected with HIV still exceeds the 
number of people starting HIV treatment each year – too many people are 
acquiring HIV, and not enough people eligible for treatment in accordance with 
the WHO guidelines are receiving it, especially after the recent 2015 recom-
mendation that ART should be initiated in all PLHIV regardless of CD4 cell 
count (WHO 2014a, WHO 2015a). However, even PLHIV who have been 
linked to HIV care may drop out of the system – globally the median retention 
in care rate at 12 months is about 86% and a gradual decrease to 73% after 
5 years has been observed (WHO 2014a). Research has also revealed that about 
one quarter of patients temporarily interrupt treatment (Kranzer & Ford 2011) 
and another quarter appear to drop out of care within 3 years (Fox & Rosen 
2010). While several methods to improve retention in care, including various 
types of ART adherence support interventions, have been developed, only pro-
found knowledge of local epidemiological situation and healtcare system, 
including the main barriers to access, will enable the selection of the best and 
most suitable (counter)measures.  
Estonia, with HIV incidence constantly decreasing since 2006, stood out in 
the European Union/European Economic Area (EU/EEA) with the highest rate 
of new HIV cases (22.1 per 100 000) in 2014. Based on the 2014 rate of AIDS 
diagnoses (1.4 per 100 000) Estonia no longer belongs to the top 3 countries in 
EU/EEA (as in past 3 years), now ranking 6th–7th. Since 2011, deaths among 
people diagnosed with HIV and/or AIDS in Estonia have been decreasing 
(ECDC/WHO Regional Office for Europe 2015). Estonia’s capacity to manage 
its response to HIV and AIDS has greatly increased over the past decade, and 
HIV medical care (including ART) is free of charge for PLHIV, regardless of 
their medical insurance status (Laisaar et al. 2011, PAPER IV). However, to 
maximize both the individual and public health benefits of ART, the health 
system must ensure an effective cascade of high quality services provided to 
PLHIV to enable them obtain ART (Nosyk et al. 2014). 
 
This work focuses on people living with HIV, and ART as the cornerstone of 
their (individual) response to HIV. Adequate long-term adherence to ART, 
however, is essential not only for individual, but also for the public health benefit 
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the treatment can provide – impeding the emergence of drug-resistance and 
virus transmission (Altice et al. 2001, WHO 2003, Mannheimer et al. 2005, 
Chesney 2006, Ray et al. 2010, Cohen et al. 2011, WHO 2015a). Thus, we aimed 
to study factors influencing ART adherence among PLHIV engaged in HIV care 
in Estonia, and develop a tailored ART adherence support intervention program 
with possible applications in further development of HIV treatment services in 
Estonia, and potentially in neighbouring countries with similar socio-economic 
and HIV epidemic evolution. As regular assessment and promotion of safe 
sexual practices to reduce HIV transmission risk are also considered an essential 
component of the package of support provided to PLHIV in HIV care (WHO 
2008, CDC et al. 2014, DHHS 2015, EACS 2015), this work also includes a 
study of sexual risk reduction interventions applicable to the epidemiological 
and transitional healthcare context in Estonia, and potentially to other countries 
in Eastern Europe. 
This work also contributes to the fast evolving international knowledge base 
on PLHIV engagement in HIV/AIDS care by describing and quantifying the 
spectrum of PLHIV engagement in HIV care in Estonia. Identification of the 
main gaps in the care system performance can assist Estonian policymakers and 
service providers to develop system improvements and enhance services that 
best support PLHIV as they move through the continuum of HIV care. 
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2. REVIEW OF THE LITERATURE 
2.1. The HIV epidemic 
2.1.1. The HIV epidemic in the world 
Worldwide, by end of 2014 about 37 million people were estimated to live with 
HIV, with 2 million (1.9–2.2 million) of them newly infected in 2014 (UNAIDS 
2015a). Although during the past 15 years considered in this work (2000–2014), 
new infections have come down by more than 1/3 from the 3.1 million (3.0–
3.3 million) in 2000, over the total course of the epidemic altogether more than 
39 million people have been lost to HIV – died from AIDS. Although since 
2006 the global number of AIDS-related deaths has been constantly decreasing, 
in 2014 AIDS still accounted for 1.2 million (980 000–1.6 million) deaths 
(UNAIDS 2015a).  
The epidemic patterns i.e., the level, main transmission mode(s) of the virus, 
most vulnerable population groups, and AIDS-indicative diagnoses have varied 
across the different regions of the world, reflecting the diversity in HIV epi-
demiology. With Estonia located in Europe, this work further provides an over-
view of the HIV epidemic in the WHO European Region, one of the 6 world 
regions by WHO (WHO 2016). 
 
 
2.1.2. The HIV epidemic in Europe 
2.1.2.1. HIV cases in Europe 
In the WHO European Region, by the end of 2014 altogether 1 840 136 people 
had been diagnosed with HIV over the course of the epidemic. Of those, 995 
175 diagnoses were officially reported to the joint ECDC/WHO Regional Office 
for Europe surveillance system, and an additional 907 607 infections were 
diagnosed in Russia. In past 15 years, the HIV epidemic in Europe had escalated 
from 21 337 new cases (4.1 per 100 000) diagnosed in 2000 to 56 945 (7.9 per 
100 000) in 2014 (ECDC/WHO Regional Office for Europe 2010, ECDC/WHO 
Regional Office for Europe 2015). Within European Union/European Economic 
Area (EU/EEA), the rate of new diagnoses increased from 6.6 per 100 000 in 
2000 to 6.9 in 2008, and has thereafter decreased to 5.9 per 100 000 by 2014 
(ECDC/WHO Regional Office for Europe 2010, ECDC/WHO Regional Office 
for Europe 2015). 
In 2014, 142 197 people were newly diagnosed with HIV in 50 of the 53 
WHO European Member States, being the highest annual number since the 
reporting started in the 1980s (ECDC/WHO Regional Office for Europe 2015). 
Of those, 40% (56 945 cases) were officially reported by 49 (of the 50) coun-
tries, with almost half (29 992 cases) originating from EU/EEA. Among the 49 
countries the rate was 7.9 per 100 000 population, compared to the 5.9 per 
100 000 in EU/EEA. However, when also considering the 85 252 new diagnoses 
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registered in Russia by the Federal Scientific and Methodological Centre for 
Prevention and Control of AIDS, the actual rate of new HIV cases in the WHO 
European Region would have equaled 16.4 per 100 000 (ECDC/WHO Regional 
Office for Europe 2015).  
It has been recognized that in Europe, instead of the politico-economic 
division of countries into EU/EEA and non EU/EEA, the geographical grouping 
[into West, Centre and East (see Figure 1)] better reflects the epidemiological 
pattern(s) of the HIV epidemic(s) in the Region (ECDC/WHO Regional Office 
for Europe 2015). In general, the epidemic in EU/EEA mostly mirrors that in the 
West, as majority of countries in EU/EEA (18 of the total 31) are located in that 
area. While Estonia belongs to EU already since 2004, the main HIV epidemic 




West (23 countries): Andorra, Austria*, Belgium*, Denmark*, Finland*, France*, Germany*, Greece*, 
Iceland, Ireland*, Israel, Italy*, Luxembourg*, Malta*, Monaco, Netherlands*, Norway, Portugal*, San 
Marino, Spain*, Sweden*, Switzerland, United Kingdom* 
Centre (15 countries): Albania, Bosnia and Herzegovina, Bulgaria*, Croatia*, Cyprus*, Czech Republic*, 
Hungary*, the former Yugoslav Republic of Macedonia, Montenegro, Poland*, Romania*, Serbia, Slovakia*, 
Slovenia*, Turkey 
East (15 countries): Armenia, Azerbaijan, Belarus, Estonia*, Georgia, Kazakhstan, Kyrgyzstan, Latvia*, 
Lithuania*, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan  
*EU Member State as of July 1, 2014 
 
Figure 1. Geographical division of the WHO European Region ((ECDC/WHO 
Regional Office for Europe 2015). 
 
 Across the 49 countries that provided their 2014 data to ECDC/WHO, 43% of all 
people newly diagnosed with HIV (24 669) were reported in the East (including 
Estonia) with a rate of 22.3 per 100 000, 48% in the West (6.4 per 100 000 





also considering the available 2014 data from Russia, an otherwise nonreporting 
(to ECDC/WHO) country in the East of the European Region, the rate of new 
infections in the East would almost double (43.2 per 100 000 population). At 
country level, the highest rates of newly diagnosed infections in Europe for 
2014 were observed in Russia (58.4 per 100 000 population), Ukraine (36.9), 
and Estonia (22.1), all from the East area (ECDC/WHO Regional Office for 
Europe 2015).  
During the HIV epidemic in Europe, cumulatively the biggest proportion of 
newly diagnosed cases have been reported among people aged 30–39. This also 
applies to 2 of the 3 geographic areas of the Region i.e., the East and West, both 
during 2000–2014 and the total course of the epidemic(s). In the Centre, people 
aged 20–29 have prevailed (EuroHIV 2005, ECDC/WHO Regional Office for 
Europe 2015). In 2014, over a third (36%) of people newly diagnosed with HIV 
in the Region were aged 30 to 39. The rate for new cases for men was 2.4 times 
higher than for women (11.1 and 4.7 per 100 000 population, respectively), with 
the male-to-female ratio lowest in the East (1.4.), higher in the West (3.3), and 
the highest in the Centre (4.4) (ECDC/WHO Regional Office for Europe 2015). 
While back in 2000 and 2001 people in Europe (the WHO European Region) 
were infected with HIV mainly through injection drug use, since 2002 
(cumulatively) HIV has been mainly acquired through heterosexual contact, 
with already more than 50% of all newly registered cases in 2014 attributable to 
this mode of transmission (EuroHIV 2005, ECDC/WHO Regional Office for 
Europe 2015). In the East, however, majority of new infections were acquired 
through injection drug use until 2008, when the proportion of new cases 
attributable to heterosexual contact started to increase rapidly (EuroHIV 2005, 
ECDC/WHO Regional Office for Europe 2015). Although in 2014 heterosexual 
transmission already accounted for 2/3 of all newly diagnosed cases reported 
from the East, still more than ¼ were related to IDU. When also reckon with 
2014 data from the fastest evolving epidemic in the area and whole Europe i.e., 
Russia, where more than half of people with known mode of transmission were 
infected through IDU, the significance of HIV transmission attributable to IDU 
would be remarkably higher in the East. Whereas in the West and the Centre, in 
2014 sex between men was the leading transmission mode (44% and 28%, 
respectively) (ECDC/WHO Regional Office for Europe 2015). 
In 2014, information on CD4 cell counts of people newly diagnosed with HIV 
was only provided by 22 of the officially reporting (to ECDC/WHO) countries 
for less than 2/3 of people newly diagnosed. Although the data were alarming – 
in all the areas of the Region HIV was detected late in the course of the disease 
(at diagnosis 48% of PLHIV having CD4 cell count < 350 cells/mm3, and 
another 28% < 200 cells/mm3), further assessment could only be performed on 




2.1.2.2. AIDS cases, morbidity and mortality in Europe 
By the end of 2014, the number of people diagnosed with AIDS in the WHO 
European Region had approached half a million (487 087), with 451 667 diag-
noses officially reported to ECDC/WHO, and another 35 420 diagnosed in 
Russia (ECDC/WHO Regional Office for Europe 2015). In past 15 years 
(2000–2014), the rate of new AIDS diagnoses increased by 29% from 1.7 (12 
416 cases) to 2.3 (16 037 cases), respectively. However, within the different 
geographic areas of the Region the trends have varied greatly. While the East 
has experienced a 15-fold increase from 0.7 per 100 000 in 2000 (982 cases) to 
10.7 in 2014 (11 890 cases), a steady 69% decline has been observed in the West 
from 2.6 per 100 000 (10 464 cases) to 0.8 (3 214 cases) (ECDC/WHO Regional 
Office for Europe 2010, ECDC/WHO Regional Office for Europe 2015). The 
yearly rate of AIDS cases diagnosed in the East has exceeded the rate in the 
West from 2004 on (ECDC/WHO Regional Office for Europe 2010). In the 
Centre, the rate (0.5 per 100 000) has not changed from 2000 to 2014 (with only 
970 and 932 cases registered in 2000 and 2014, respectively), although was 
lower for a meantime (around 0.4 in 2001–2011) (ECDC/WHO Regional Office 
for Europe 2010, ECDC/WHO Regional Office for Europe 2015). In 2014, 74% 
of people newly diagnosed with AIDS (11 890) were reported from the East, 20% 
(3 214) from the West and 6% (932) from the Centre of the Region (ECDC/WHO 
Regional Office for Europe 2015). 
In Europe, the format of collecting HIV/AIDS surveillance data has under-
gone several changes during the past 15 years. This especially applies to infor-
mation on diseases indicating AIDS, e.g., data by geographic area are only 
available since 2002, and on area level differentiation between pulmonary and 
extrapulmonary tuberculosis has only been made since 2008. Although 
throughout the years on the WHO European Region level most of AIDS cases 
could be attributed to tuberculosis (ECDC/WHO Regional Office for Europe 
2009 – ECDC/WHO Regional Office for Europe 2015, EuroHIV 2004 – Euro-
HIV 2007, ECEMA 2001 – ECEMA 2003), distinct patterns have been observed 
within the different areas of the Region. In the East, pulmonary tuberculosis has 
been the most common AIDS-indicative disease since 2008, accounting yearly 
for around 30% of all disease events, with wasting syndrome and oesophageal 
candidiasis ranking 2nd and 3rd (ECDC/WHO Regional Office for Europe 
2009 – ECDC/WHO Regional Office for Europe 2015). However, by 2014 also 
the frequency of extrapulmonary tuberculosis (not reaching the top 3 in previous 
years) had increased, and altogether Mycobacterium tuberculosis indicated 
AIDS in almost 40% of the cases (ECDC/WHO Regional Office for Europe 
2015). Meanwhile, in the West the most common diseases (pneumocystis 
pneumonia and oesophageal candidiasis; and pulmonary tuberculosis among the 
3rd to 5th) have not changed since 2008, when data collection in the current 
format started. In the Centre, ‘wasting syndrome due to HIV’ has been the most 
common AIDS-indicative disease, with pulmonary tuberculosis switching places 
with pneumocystis pneumonia in 2009 and becoming (and remaining) the 2nd 
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most common disease (ECDC/WHO Regional Office for Europe 2009 – ECDC/ 
WHO Regional Office for Europe 2015).  
By the end of 2014, in Europe altogether 263 727 people diagnosed with HIV 
and/or AIDS had died (since the reporting started), with 235 466 officially 
reported to ECDC/WHO and an additional 28 261 in Russia. In 2014, vast 
majority (78% of the 5 052) deaths among people diagnosed with HIV and/or 
AIDS in the officially reporting countries (with 45 providing the data) had 
occurred in the East, and only 15% in the West and 7% in the Centre 
(ECDC/WHO Regional Office for Europe 2015). When considering the past 15 
years, the number of deaths among AIDS cases in the total Region reached the 
peak in 2005 and has been decreasing since (ECEMA 2001, ECEMA 2003, 
ECDC/WHO Regional Office for Europe 2015). Although changes in case defi-
nitions and data provison issues inhibit detailed analysis of the trend(s) in 
Europe, disparities by geographic area are evident. In the East, over the past 
decade (with data available in the current format), the number of deaths among 
AIDS cases has increased by 55% (from 2 553 in 2005 to 3 941 in 2014), 
whereas mortality in the West has been steadily decreasing (altogether more 
than 4 times), and has remained low in the Centre throughout the decade (with 
369 cases reported in 2005, and 365 in 2014) (ECDC/WHO Regional Office for 
Europe 2015). 
2.1.3. The HIV epidemic in Estonia 
2.1.3.1. HIV cases in Estonia 
In Estonia, the number of people diagnosed with HIV reached 8 993 by the end 
of 2014 (EHB 2015). After HIV was first detected in Estonia in 1988, the rate of 
new cases remained low for the following 12 years (reaching 0.9 per 100 000 by 
1999) (EHB 2015, Statistics Estonia 2015). Half of the cases were identified 
among homo- or bisexual men, and the rest were presumably acquired hetero-
sexually (Ustina et al. 2001). A significant change occurred in the summer of 
2000, when the number of new cases, predominantly among people who inject 
drugs (PWID), was noted to increase rapidly. Officially an epidemic of HIV in 
Estonia was recognized in 2001. Although by 2014 the rate of new HIV 
diagnoses had more than halved since the peak in 2001 (from 45.7 to 22.1 per 
100 000), the 291 new cases diagnosed in 2014 still placed Estonia first in 
EU/EEA, and second in both the East and the total WHO European Region 
(among countries officially reporting to ECDC/WHO i.e., excluding Russia) 
(Laisaar et al. 2011, ECDC/WHO Regional Office for Europe 2015, EHB 2015, 
Statistics Estonia 2015).  
Since the beginning of the epidemic PWID have been disproportionately 
represented in the HIV-positive population in Estonia (ECDC/WHO Regional 
Office for Europe 2015). However, in 2010 newly diagnosed infections acquired 
through heterosexual contact exceeded those related to IDU, a change observed 
in several other countries in the East (e.g., Ukraine, Latvia, Belarus) already in 
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2008 (Laisaar et al. 2011, ECDC 2015). However, in 2014, when nearly half of 
the new cases in Estonia (46%) had been reportedly acquired heterosexually, 
and only 23% through IDU, the transmission mode remained unknown in 19% 
of the cases (ECDC/WHO Regional Office for Europe 2015, EHB 2015).  
The HIV epidemic in Estonia has had a distinctive geographic distribution – 
the two regions most affected i.e., contributing the majority of new HIV cases, 
have been Ida-Viru county in the easternmost part of the country on the Russian 
border, where the Estonian epidemic erupted in the chief city Narva in 2001, 
and Harju county (including Tallinn, the capital of the country). In 2014, these 
two regions still accounted for 92% of all the new HIV cases registered in the 
country. Although the absolute numbers of new cases in Harju and Ida-Viru 
were similar (145 and 122, respectively), the rate was by far the highest in Ida-
Viru with 82 per 100 000 inhabitants, compared to 25 in Harju, and 22 in 
Estonia in general (EHB 2015, Statistics Estonia 2015). 
During past 15 years, more than two-thirds (67%) of new HIV cases in 
Estonia have been diagnosed among men. Although the absolute number of 
newly infected women has not substantially changed from 2000 to 2014 (78 and 
110 cases registered, respectively), the proportion of women has almost doubled – 
from 20% in 2000 to 38% in 2014 (EHB 2015a). Unlike in the WHO European 
Region Europe (in total) and in the East area of it, most new HIV cases in 
Estonia have been diagnosed in people below the age of 30, both cumulatively 
and on yearly basis (2000–2014). Yet the mean age at diagnosis has been 
increasing. While in 2001, the year the epidemic erupted, 92% of new cases 
were registered among people under 30 years of age, in 2014 the corresponding 
proportion was only 31% (Laisaar et al. 2011, EHB 2016a). 
 
2.1.3.2. AIDS cases, morbidity and mortality in Estonia 
The first AIDS case in Estonia was diagnosed in 1992, 4 years after the first 
case of HIV infection. Although the number of AIDS cases increased rapidly 
from 3 (0.2 per 100 000 population) in 2000 to 61 (4.6 per 100 000) in 2008, a 
decrease has been observed thereafter – to 18 cases in 2014 (1.4 per 100 000) 
(ECDC/WHO Regional Office for Europe 2010, ECDC/WHO Regional Office 
for Europe 2015).  
Altogether in past 15 years (by end of 2014), a total of 434 individuals were 
diagnosed with AIDS in Estonia (EHB 2015), with ‘tuberculosis and other 
mycobacterial diseases’ most frequently indicating AIDS, both cumulatively 
and on yearly basis with data available since 2007 (EHB 2012, EHB 2016). In 
2014, tuberculosis was still the most common AIDS-indicative disease in 
Estonia (in 7 of the 20 newly diagnosed AIDS cases), alike in the total East area 
of the WHO European Region (ECDC 2015, EHB 2016b).  
The first AIDS death in Estonia was reported in 1996, and according to 
national mortality statistics the cumulative number of deaths attributable 
primarily to AIDS had reached 510 by the end of 2014, with a peak (60 deaths 
registered) in 2011, and a gradual decrease thereafter (to 45 cases in 2014) 
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(Statistics Estonia 2015). However, these numbers do not include deaths among 
people diagnosed with AIDS for causes other than AIDS, including overdose-
related deaths among HIV-positive PWID, the population group most affected 
by HIV in Estonia.  
 
 
2.2. Confronting the HIV epidemic 
2.2.1. Antiretroviral therapy for people living with HIV 
Without treatment, most HIV-infected individuals eventually develope progres-
sive immunodeficiency, as evident by CD4 T lymphocyte depletion, that leads 
to AIDS-defining illnesses and premature death. Although effective response to 
HIV/AIDS is multidimensional, this work focuses on antiretroviral therapy 
(ART), a fundamental element in confronting the disease and epidemic.  
The era of ART began in 1986 with azidothymidine (AZT), also known as 
zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI) (Fischl et al. 
1987). The goal of the treatment was to inhibit HIV replication. However, it soon 
became clear that response to the therapy ― zidovudine, and also other nucleo-
sides that soon followed, varied at the different stages of the disease and declined 
over time (Hammer et al. 1996). Thus, the idea of combining antiretroviral drugs 
emerged (Caliendo & Hirsch 1994, Hammer et al. 1996). Although during the 
following decade dual therapy became well established, the clinical effect on 
morbidity and mortality remained limited (Hammer et al. 1996).  
In 1996, cogent evidence on the effect of triple combination antiretroviral 
regimens (including protease inhibitors) targeting different steps of viral repli-
cation to control HIV was presented at the 11th International Conference on 
AIDS (Cohen & Fauci 1998, Fauci & Marston 2015). In such combination, 
antiretrovirals were able to inhibit HIV replication so that plasma HIV RNA 
level (viral load) was kept below detectable (by commercially available assays) 
level. Durable viral suppression, in turn, improved the immune function i.e., 
health and overall quality of life of PLHIV. Ever since, the amount of evidence 
that triple-drug combinations, known as ‘potent combined or highly active ART 
(HAART)’, reduce illness and death among PLHIV has been growing expo-
nentially (Sidibe et al. 2014). It has been estimated that since 2000 the rollout of 
combined ART has saved about 7.8 million lives worldwide (Fauci & Marston 
2015).  
However, while weighing the benefits and risks of the treatment at the 
different stages of the disease, evidence on when (at what CD4 cell count) to 
initiate the treatment had to be gathered (Fauci & Marston 2015). First, the 
Strategies for Management of Antiretroviral Therapy (SMART) study, published 
in 2006, confuted the fear (in fact risk) of toxic, especially cardiovascular, effects 
with long-term ART, compared to all the opportunistic illnesses and death 
avoided with the help of it (The SMART Study Group 2006). Subsequently, the 
HIV Prevention Trials Network (HPTN) 052 study, published in 2011, and the 
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Intervention Préventive de l’Exposition aux Risques avec et pour les Gays 
(IPERGAY) study from 2015, confirmed the evidence from previous cohort and 
surveillance studies that early ART initiation significantly reduces HIV trans-
mission (Cohen et al. 2011). Still, reaching consensus on whether initiating 
treatment at (near) normal CD4 cell counts (> 500 cells/mm3) would also benefit 
the person taking the treatment, required time and additional evidence (Piot & 
Quinn 2013, Fauci & Marston 2015). When finally results from two pivotal 
randomized controlled trials START and TEMPRANO had demonstrated that 
clinical benefits of ART are greater when ART is started early in the course of 
the disease (The INSIGHT START Study Group 2015, The Temprano ANRS 
12136 Study Group 2015), by end of 2015 all major ART guidelines had 
introduced a concordant recommendation that the treatment should be initiated 
in everyone living with HIV regardless of the CD4 cell count (Günthard et al. 
2014, DHHS 2015, EACS 2015, IAPAC 2015, WHO 2015a).  
In 2000, when the World Health Organization (WHO) and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) started setting global targets to 
ART access (among other measures) to slow the growth of the global AIDS epi-
demic, not every PLHIV was considered clinically eligible for the treatment. Soon 
the global target was detailed and, with data and evidence building, has been 
steadily raised over the years, reaching 15 million by 2015 (UNAIDS 2015b). In 
mid 2015 there were an estimated 15.8 million people of the about 37 million 
living with HIV in the world accessing ART (UNAIDS 2015a, UNAIDS 2015b).  
In Europe, data on ART coverage has been gathered by ECDC since 2009 
i.e., the 2010 reporting round. However, due to inconsistent reporting, European-
level information on HIV treatment over time is limited to 29 countries (ECDC 
2013a, ECDC 2013b, ECDC 2015a). Although in these countries the number of 
PLHIV receiving ART has almost doubled in past 5 years, there is evidence to 
suggest that disparities in treatment coverage between high-, and low- and 
middle-income countries still exist (WHO 2013a), and in several countries in 
the Region some key populations still experience difficulties in accessing ART 
(ECDC 2014). 
In Estonia, HIV medical care (including combined ART) is free of charge for 
PLHIV, regardless of their medical insurance status, and is mainly provided by the 
government healthcare system through infectious disease clinics/departments in 
five major hospitals. The European AIDS Clinical Society (EACS) HIV treatment 
guidelines have been followed i.e., until October 2015 ART was recommended 
for any HIV-positive person without prior ART exposure with a CD4 cell count 
< 350 cells/mm3, and carefully considered also for people in special conditions 
with CD4 cell counts above this level (EACS 2013, EACS 2014). Prophylactic 
treatment to avoid HIV vertical transmission has also been available to all HIV-
infected pregnant women during both pregnancy and delivery, and to their new-
borns. In Estonia, in past 15 years the number of patients on combined ART has 
increased from 27 in 2000 to 3 025 in 2014 (Laisaar et al. 2011, EMSA 2016).  
With regards to ART, this work focuses on HIV treatment in people living 
with HIV.  
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2.2.1.1. Adherence to antiretroviral therapy 
Adherence in the context of ART is the extent to which a person’s behavior – 
taking antiretroviral (ARV) drugs corresponds to agreed recommendations from 
a healthcare provider (WHO 2003). This includes not only timing and dosing, 
but also consistency in taking the drugs (Chaiyachati et al. 2014). 
Adherence is central to ART success – obtaining control over HIV repli-
cation and maintaining CD4 cell count within normal range. Adequate long-
term adherence is essential not only for individual, but also for the public health 
benefit the treatment can provide – impeding the emergence of drug-resistance 
and virus transmission (Altice et al. 2001, WHO 2003, Mannheimer et al. 2005, 
Chesney 2006, Ray et al. 2010, Cohen & Fauci 2011, WHO 2015a).  
Current once daily ART regimens, including those with low pill burden, 
without a food requirement, and with few side effects, have been associated with 
higher levels of adherence (Parienti et al. 2009, Raboud et al. 2011, Nachega et 
al. 2014). Still, even these more simplified regimens may be challenging to 
follow over time (Simoni et al. 2003, Amico et al. 2006, Bae et al. 2011).  
Adherence is the result of a multilayer process involving acceptance of the 
diagnosis, perception of the need to follow the recommended treatment, and 
motivation to do so. Furthermore, appropriate skills to not only reach, but also 
maintain an optimal level of adherence over time, and ability to overcome any 
difficulties that may appear, are essential. 
Medication adherence, a complex behavior, is influenced by multiple 
determinants belonging to different domains: the patient, the disease (state), the 
treatment, the treatment provider, the patient-provider relationship, and the 
healthcare system (Ammassari et al. 2002, DHHS 2015, WHO 2015a). Due to 
HIV-related stigma and discrimination, supportive social environment also 
plays a significant role in easing adherence (Rintamaki et al. 2006, Rao et al. 
2007, WHO 2015a). From the patient perspective, failure to adopt practices that 
facilitate adherence, such as linking medication taking to daily activities or 
using a medication reminder system, is often associated with treatment failure 
(Fisher et al. 2006, Wolf et al. 2007, Holzman et al. 2015). Individual patient 
factors may also include limited understanding of the disease and the benefits of 
ART, lack of interest or desire to take the medicines, forgetting doses, being 
away from home or other changes in daily routine, depression or other illness 
(Pence 2009, Holzman et al. 2015), and substance or alcohol abuse (Lucas 2011, 
Holzman et al. 2015, WHO 2015a). Treatment-related factors may include heavy 
bill purden or complexity of the dosing regimen, dietary prerequisites, and drug 
adverse events (DHHS 2015, Genberg et al. 2015, WHO 2015a). Healthcare 
system factors include distance to health services (Tuller et al. 2010), long 
waiting times to receive care and obtain refills, and the burden of direct and 
indirect costs of healthcare (Genberg et al. 2015, WHO 2015a). Due to the 
complex nature of the phenomenon, failure to adhere is often a consequence of a 
combination of barriers from different domains (Carr & Gramling 2004, Halkitis 
et al. 2005, Stirratt et al. 2006, DHHS 2015, Genberg et al. 2015, WHO 2015a).  
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Measurement of medication adherence is challenging because adherence is 
an individual patient behavior. Several methods, often classified as subjective, 
objective, or biological, and validated instruments are available to assess 
adherence (Chaiyachati et al. 2014). The most feasible and thus most frequently 
used measure of adherence is self-report (Chaiyachati et al. 2014). Despite that 
patients may overestimate adherence, it still allows to assess adherence over 
time and, unlike other i.e., objective measures, self-report, when completed at 
each clinic visit, enables to detect any barrier(s) to adherence the earliest and 
intervene immediately (DHHS 2015). The other measures of adherence include 
pharmacy records and pill counts (Chaiyachati et al. 2014). Pharmacy records 
can be valuable when medications are obtained exclusively from a single source 
so that refills can be traced. Pill counts are also common, but can be altered by 
patients. Therapeutic drug monitoring and electronic measurement devices [e.g., 
Medication Event Monitoring System (MEMS) bottle caps] are also an option, 
but are costly and thus used primarily in research settings. The most reliable 
indicator of adherence is viral load suppression, a biological outcome deter-
mined by adherence behavior. When patients initiating ART fail to achieve viral 
suppression by 24 weeks of treatment, the possibility of suboptimal adherence 
should always be assessed, along with excluding the possibility of the patient 
harboring resistance mutations to any of the drugs (DHHS 2015). Optimal viral 
suppression is generally defined as viral load persistently below the level of 
detection (HIV RNA < 20 to 75 copies/mL, depending on the assay used 
(DHHS 2015, EACS 2015). As for monitoring response to ART, combining 
viral load measurement routinely every 3–6 months (DHHS 2015, EACS 2015) 
or less frequently (WHO 2013b) with other adherence evaluation methods may 
yield most beneficial to the patient results. 
Regardless of how treatment adherence is measured, the adequate level for 
adherence has to be defined. In the earliest ART adherence studies the cut-off 
point for adherence was derived from the level of adherence proved to be effec-
tive in tuberculosis prophylaxis (e.g., > 80%) (Turner 2002). The optimal level 
for ART adherence – taking at least 95% of pills as prescribed, was defined by 
Chesney and colleagues in 2000 (Chesney et al. 2000), and has not been over-
ruled. At 95% (or higher) adherence the virus was detectable i.e., treatment failure 
occurred in only 10% of the patients studied, compared to treatment failing in 
almost half (47%) of patients with adherence between 80% and 90% (Chesney 
et al. 2000). However, there is some evidence suggesting that the optimum may 
differ for different classes of ARV drugs (Maggiolo et al. 2005, Bangsberg 
2006, Apisarnthanarak & Mundy 2010). The cut-off also depends upon the 
measure used (Turner 2002). For instance, when measuring adherence by self-
report, dichotomizing at 100% may be most valid for statistical analyses, given 
that these continuous values are highly skewed and non-normal, yet as a clinical 
goal, this level may be unreasonable for patients in the long term. One could 
also question whether patients can reliably distinguish between less than 80% or 
less than 85% (or any other selected level) when reporting their adherence 
(Simoni et al. 2006a). Regardless of evidence that long-term viral suppression 
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requires near-perfect adherence, average rates of adherence to ART around 70% 
have been observed over the years (Low-Beer et al. 2000, Bangsberg 2001, 
Paterson et al. 2000, Golin et al. 2002).  
Despite international research efforts to examine ART adherence in diverse 
populations, there is limited information currently available concerning ART 




2.2.2. The continuum and the cascade of HIV care  
for people living with HIV 
Potent combined antiretroviral therapy (ART) has transformed HIV infection 
from a (sub)acute to a chronic disease, and has significant effects on preventing 
HIV transmission to HIV-uninfected partners (Cohen & Fauci 2011, UNAIDS 
2014b). Yet to maximize the health benefits of ART and to provide it to all in 
need, health systems must ensure an entire cascade of high quality services to 
PLHIV (Nosyk et al. 2013). Thus also adherence to ART has been recently 
conceptualized more broadly – including timely engagement and sustained 
retention in HIV care (DHHS 2015).  
In the United States in 2005, looking further from the already proven indi-
vidual benefit of ART to its population-level effectiveness, Giordano and 
colleagues pointed out that for the treatment to be effective for the population 
infected with HIV, certain steps needed to be followed in HIV care: those infected 
had to be diagnosed, enter care, receive ART, and adhere to it (Giordano et al. 
2005). Concurrently, the HIV/AIDS Bureau in the Health Resources and 
Services Administration (U.S. Department of Health and Human Services) 
developed a continuum of engagement in HIV care model, defining people from 
‘not aware of infection’ to ‘fully engaged in care’, potentially moving both 
directions i.e., entering and dropping out of the system of HIV care (Cheever 
2007). The HIV/AIDS treatment cascade as a model to map the proportion of 
PLHIV actually receiving the medical care they need for HIV at each step in the 
care continuum, was first applied in the United States by Greenberg and 
colleagues to the Washington, D.C. area in 2009, then by Gardner and colleagues 
on national level in 2011, and has been since utilized by the Centers for Disease 
Control and Prevention (CDC) to monitor PLHIV engagement in HIV care in 
the country (Greenberg et al. 2007, Gardner et al. 2009, CDC 2014, Giordano 
2015). In 2014, the European Centre for Disease Prevention and Control 
(ECDC) also added several questions pertinent to HIV continuum of care to data 
collection when monitoring the HIV epidemic(s) and performance of national 
HIV care programs in Europe (ECDC 2015b). 
Over time, the HIV care cascade model has evolved. Some elements of the 
cascade appear in most reports/presentations from the constantly increasing 
number of countries studying their HIV care systems according to this model – 
the estimates of people living with HIV, those having been diagnosed with HIV, 
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those on ART, and those known to be virally suppressed. Linkage to and reten-
tion in HIV care are also commonly included (ECDC 2015b, Levi et al. 2015). 
However, some cascades also include other categories, such as PLHIV in need 
of ART (Del Rio 2012, Pokrovskaya et al. 2014), or start the cascade from a 
different (from the PLHIV) population (Levi et al. 2015, WHO 2015b).  
Although international organizations and institutions monitoring the evo-
lution of the HIV epidemic and response to it have recently intensified efforts to 
define the steps and definitions to be used when studying and presenting the 
cascade(s) (WHO 2014b, ECDC 2015b, WHO 2015b), currently data across 
countries should still be compared or aggregated with great caution due to the 
methodological diversity. Still, quantifying the steps of the cascade within a 
country or region enables service providers and policymakers in that area to 
identify the main ‘local’ gaps in providing PLHIV sustained and high quality HIV 
care, and implement optimal ‘local’ system improvements and service enhance-
ments that best support ‘local’ people as they move through the continuum of 
care.  
In 2014, UNAIDS announced an ambitious goal to end the HIV/AIDS epi-
demic in the world by 2030. Special targets, corresponding to 4 of the steps in 
the HIV care cascade, were set: (i) 90% of people living with HIV should know 
their HIV status, (ii) 90% of people diagnosed with HIV should receive ART, 
and (iii) 90% of people on ART should have viral suppression. Modelling sug-
gests that achieving these targets by 2020 would enable the world to end the 
AIDS epidemic by 2030 (UNAIDS 2014b, UNAIDS 2014c). In order to attain 
the 90–90–90 targets, efforts are needed to optimize the HIV care continuum. 
The cascade of HIV care enables to map HIV care systems, uncovering the 
steps where improvements are needed foremost.  
 
 
2.2.3. Prevention with people living with HIV  
In confronting the HIV epidemic, similarly to HIV treatment, also in HIV pre-
vention the advantages of a combined approach have been recognized. The 
concept of ‘highly active retroviral prevention (HARP)’ i.e., combining poten-
tially synergistic prevention activities into a single, all-inclusive program was 
proposed by King K. Holmes already in 2007 (Vandenbruaene 2007). ‘Combi-
nation prevention’ is currently the more widely used term in HIV prevention 
programming (UNAIDS 2010). Combination prevention relies on simultaneous 
use of complementary behavioral, biomedical and structural prevention strategies 
(UNAIDS 2010, Bekker et al. 2012). Biomedical interventions comprise clinical 
and medical approaches to reduce HIV transmission: antiretroviral (ARV) drugs 
for the prevention of mother-to-child transmission, pre- and post-exposure pro-
phylaxis, and treatment as prevention; and sex and reproductive health services 
(UNAIDS 2010). However, biomedical interventions are rarely implemented 
independently, as even those with proven efficacy are affected by human 
behavioral factors (adherence and risk compensation) and thus rely on behavioral 
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interventions to strengthen their effectiveness (Padian et al. 2008, UNAIDS 
2010). HIV combination prevention programs can be implemented on different 
levels (e.g., individual, relationship, community, societal) (UNAIDS 2007). 
Choosing the optimal package always relies on clear and evidence-informed 
understanding of the local HIV epidemic and setting (e.g., the infrastructure, 
culture and traditions) – the approach often referred to as ”Know Your Epidemic/ 
Know Your Response” (UNAIDS 2007, UNAIDS 2010).  
In preventing HIV transmission, the more traditional focus from protecting 
HIV-negative individuals from becoming infected has gradually expanded to 
HIV-positive people, and helping them to avoid spreading the infection to their 
sex and injection drug use partners, and infants born to HIV-infected mothers 
(Bekker et al. 2012). It has been recognized that, from a public health perspec-
tive ‘prevention with positives’ i.e., targeting the fewer HIV-positives than the 
many HIV-negatives could be more efficient to fight the HIV epidemic (Kennedy 
et al. 2010, Mermin 2011, Lasry et al. 2012). This is also encompassed in the 
UNAIDS ‘test and treat’ strategy of rolling out universal HIV testing in order to 
diagnose all people living with HIV, and initiate ART regardless of CD4 cell 
count or viral load to reduce the rate of new HIV infections (UNAIDS 2014b), 
the latter currently encompassed in all major HIV treatment guidelines 
(Günthard 2014, DHHS 2015, EACS 2015, IAPAC 2015, WHO 2015a). 
Already in early 1990s, prior to the era of potent triple-combination ART, 
evidence started to build on HIV treatment also preventing the transmission of 
the virus, both from mother to child (Connor et al. 1994) and in serodiscordant 
partnerships (Musicco et al. 1994). As ART can reduce HIV viral load to very 
low (undetectable) levels not only in blood, but also other body fluids (semen, 
vaginal and rectal fluids) of HIV-infected individuals, and thus significantly 
reduce their risk of transmitting the virus to others (Granich et al. 2010, WHO 
2012), the concept of ‘treatment as prevention’ (TasP) emerged (WHO 2012). 
However, the success of TasP highly depends not only on the HIV-positive 
individual adhering to ART, but in serodiscordant partnerships also the risk 
behavior of both the partners accessing TasP – overstating the preventative 
benefits of ART might lead people to take higher behavioral risks, either sexual 
or IDU-related (Hasse et al. 2010). Although TasP includes preventive measures 
for both – people already infected with HIV (e.g., combined ART) and people at 
high risk of getting infected with HIV (e.g., prevention of mother-to-child trans-
mission, pre- and post-exposure prophylaxis, and microbicides), this work only 
focuses on people already living with HIV.  
 
2.2.3.1. Supporting antiretroviral therapy adherence 
In HIV care the ultimate goal is to achieve control over the virus – for people 
already infected with HIV translating into not only achieving, but also main-
taining viral suppression. While ART reduces HIV viral load to an undetectable 
level in the serum, replication still takes place in lymphatic reservoirs (Lorenzo-
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Redondo et al. 2016), implying that for prolonged viral suppression optimal 
ART adherence, challenging to maintain, is essential.  
Optimising ART adherence is attracting considerable research attention. 
While several systematic reviews and meta-analyses suggest that interventions 
can improve adherence (Amico et al. 2006, Simoni et al. 2006b, Charania et al. 
2014, de Bruin et al. 2010, Mbuagbaw et al. 2015), evidence on the effect on viral 
load is less consistent (Simoni et al. 2006b, Mbuagbaw et al. 2015), and some 
still question the ability of interventions to enhance ART adherence (Rueda et al. 
2006, Mathes et al. 2013). In addition to researcher initiated reviews on sup-
porting ART adherence, in 2008 the HIV/AIDS Prevention Research Synthesis 
Project at the Centers for Disease Prevention and Control (CDC) started keeping 
track of evidence-based interventions to help HIV care providers in the United 
States select interventions best befitting their practice. Currently (last updated 
on April 1, 2015) only 12 ART adherence interventions have been identified as 
having good evidence of effect (CDC 2016a).  
While adherence may be determined by a variety of factors from individual 
(patient) to system (healthcare) level, this work considers the patient dimension 
of adherence. Adherence as a behavior is a dynamic phenomenon (Remien et al. 
2003) and accrues from local circumstances and culture. Thus, an adherence 
intervention should be chosen based on or adapted to the socio-cultural context, 
feasibility, acceptability (to the patient), and healthcare system organization in 
the particular setting. Methodologies that allow greater tailoring of the inte-
vention activities to address the specific barriers and facilitators of adherence, 
likely differing from person to person receiving the intervention and at any given 
moment in time, show promise and are needed foremost (Robbins et al. 2014).  
Research has demonstrated that health promotion, including treatment 
adherence interventions are likely to benefit recipients most, when guided by 
social and behavioral science theories of health behavior and health behavior 
change (WHO 2003, Kok et al. 2004). Several systematic reviews and meta-
analyses of behavioral interventions (Amico et al. 2006, Simoni et al. 2006b, 
Chaiyachati et al. 2014) have concluded that “the most effective interventions 
used cognitive-behavioral models and shared a core set of psycho-educational 
components: (i) education about HIV and adherence; (ii) teaching self-
monitoring skills; (iii) identifying adherence barriers; (iv) improving problem-
solving skills; and (v) reframing treatment beliefs and attitudes” (Robbins et al. 
2014). Other key features noticed in studies with interventions improving 
adherence indicate that most successful interventions were delivered (i) to indi-
viduals (vs groups), (ii) over at least 12 weeks, and were (iii) targeting practical 
medication management skills (vs cognitive behavioral or motivational 
approaches) (Rueda et al. 2006). A recent systematic review by Chaiyachati and 
colleagues also found that the effects of interventions combining several 
strategies to promote adherence were similar to those including only one 
strategy, and long-term effects on adherence were either difficult to achieve or 
had not been studied (Chaiyachati et al. 2014).  
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In Eastern Europe, the number of HIV-infected patients who are being 
prescribed ART is increasing. While support for enhancing ART adherence is a 
growing area of interest amongst treatment providers, there are currently limited 
data available to guide such efforts, in Estonia specifically, but also more 
broadly among patients in Eastern Europe. Application and adaptation to the 
local context of intervention(s) to support ART adherence among PLHIV in the 
region require targeted attention.  
 
2.2.3.2. Supporting safe sexual behavior 
PLHIV linked to and retained in HIV care attend HIV care settings for a variety 
of medical services. Those regular interactions with patients provide caregivers 
great opportunity for patient education and interventions to reduce ongoing risk 
behaviors and maintain safer practices. According to the Centers for Disease 
Control and Prevention (CDC), “behavioral interventions are strategies designed 
to change persons’ knowledge, attitudes, behaviors, or practices in order to 
reduce their personal health risks or their risk of transmitting HIV to others” 
(CDC et al. 2003). Reducing sexual risk behaviors among PLHIV has been the 
focus of many behavioral interventions (Crepaz et al. 2006, Fisher et al. 2010, 
Carvalho et al. 2011, Crepaz et al. 2014). As behavior change occurs in 
incremental steps, messages delivered to patients receiving HIV care by 
clinicians or other qualified staff at HIV clinics during several or each visit 
could result in patients, over time, adopting and maintaining the suggested safer 
practices (CDC et al. 2003). 
Although majority of people make changes in their sexual behavior after 
being dianosed with HIV to avoid transmitting the infection, some continue to 
engage in unprotected sexual practices (CDC et al. 2003, The Healthy Living 
Project Team 2007, Fisher et al. 2010). As high sexual risk behavior among HIV-
infected people (CDC et al. 2003, Fisher et al. 2010) can have serious personal 
and public health consequences (Kennedy et al. 2010, Mermin 2011, Lasry et 
al. 2012), safe sexual practices should be actively promoted among PLHIV.  
Researchers in the field have identified, and the CDC HIV/AIDS Preven-
tion Research Synthesis Project has defined efficacy criteria for HIV behavioral 
interventions to help HIV prevention planners and providers select rigorously 
evaluated and effective interventions for HIV prevention within their commu-
nities (CDC 2016b). Reviews of evidence on sexual risk reduction among PLHIV 
have looked at interventions at different levels, including individual, group and 
community level interventions of very different types (Crepaz et al. 2006, 
Fisher et al. 2010, Carvalho et al. 2011, Crepaz et al. 2014). Analyses have 
shown sexual risk reduction interventions to be effective at promoting protected 
sexual intercourse among adults living with HIV/AIDS especially when guided 
by behavioral theories, and more intensive and longer in duration (Crepaz et al. 
2006, Johnson et al. 2006, Crepaz et al. 2014,). Interventions, delivered by 
healthcare providers during routine interactions with patients in medical care 
settings on an individual level, have demonstrated reduction in sexual risk 
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behavior (Crepaz et al. 2006, Crepaz et al. 2014). Although one metaanalysis of 
behavioral interventions to promote condom use among HIV-positive women 
showed behavioral interventions to have little effect, the authors did not 
discourage such interventions altogether, rather recommended combining them 
with other strategies (Carvalho et al. 2011). 
Currently, based on the body of available evidence, regular assessment and 
discussion of HIV transmission risk and related safe sexual practices is con-
sidered an essential part of the package of services provided to PLHIV in HIV 
care, and has thus been incorporated into major HIV treatment and related 
guidelines (WHO 2008, DHHS 2015, EACS 2015). In the United States, HIV 
care providers are advised to take any opportunity for brief HIV-related risk 
behavior reduction interventions whenever a patient with HIV visits (CDC et al. 
2003). However, the efficacy of such feasible clinician-delivered individual 
level behavioral interventions has still not been studied extensively, especially 
in Eastern Europe (including Estonia). Also, according to our knowledge the 
most applicable interventions to the local epidemiological and transitional 
healthcare system context in Eastern Europe have not been defined. 
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3. AIMS OF THE RESEARCH 
The general aim of this research was to describe the engagement of people 
living with HIV (PLHIV) in HIV care in Estonia and their adherence to anti-
retroviral treatment (ART), and to develop methods to support ART adherence 
and safe sexual practices among HIV-positive adults in HIV care in Estonia. 
 
The specific aims were: 
1. To describe and quantify PLHIV engagement in HIV care in Estonia, and 
identify the main gaps in coverage with applicable health services with 
implications for health system improvement (PAPER IV); 
2. To characterize ART adherence and understand factors associated with it 
among adult PLHIV receiving HIV medical care in Estonia (PAPER I, 
PAPER II); 
3. To develop a feasible evidence-based ART adherence support program 
targeting the needs of HIV-positive adults receiving HIV medical care in 
Estonia, and potentially in other countries with similar socio-economic 
history and HIV epidemic evolution (PAPER I). 
4. To systematically identify and synthesize research on interventions sup-
porting safe sexual behavior among HIV-positive adults in HIV care, pro-
vided on an individual level by caregivers in HIV care settings, applicable in 
Estonia, and potentially in other countries with similar socio-economic 






4. MATERIALS AND METHODS 
The current work is based on a research project combining quantitative and 
qualitative methods of data collection and synthesis. The research was lead by 
the HIV/AIDS research group at the Institute of Family Medicine and Public 
Health, University of Tartu. 
Research for this dissertation began in 2010 with mapping the HIV epi-
demic and response to the epidemic (from testing to treating HIV) in Estonia in 
the context of other Eastern European countries, and the trends of HIV/AIDS 
and related conditions in Estonia during the preceding decade from 2000 to 
2009 (Laisaar et al. 2011). These results are incorporated into the ‘Review of 
the literature’ of this work.  
For developing a feasible evidence-based ART adherence support program, 
tailored to the needs of HIV-positive adults in HIV medical care in Estonia, a 
study using mixed methods was conducted in 2010–2011 (PAPER I). The data 
collection was complemented by a cross-sectional study in 2010 to understand 
factors associated with ART adherence among PLHIV in HIV medical care in 
Estonia (PAPER II).  
To inform the development of an intervention supporting safe sexual prac-
tices among PLHIV in Estonia, a systematic review was conduced in 2014 
(PAPER III). 
To characterize the full spectrum of PLHIV engagement in HIV care (not 
limited to ART) in Estonia, a cross-sectional review was conducted in 2014–
2015, applying the HIV cascade of care model (PAPER IV). 
 
 
4.1. Research project on antiretroviral therapy adherence 
among HIV-positive adults receiving HIV medical care 
(PAPER I, PAPER II) 
4.1.1. Project setting, study design and procedures 
An ART adherence research project (PAPER I and PAPER II) was conducted in 
Ida-Viru Central Hospital in Ida-Viru County, the Eastern part of Estonia. In 
2010, the Infectious Diseases Department of this hospital was staffed by 3 
infectious diseases trained physicians, 8 nurses, and a part-time social worker/ 
case manager. The hospital served about 1/5 of PLHIV in medical care in 
Estonia (EHIF 2011), and ART adherence support was generally limited to 
treatment regimen information provision. 
 
PAPER I 
To identify in-clinic strategies that could leverage patient-centered practices to 
best support the specific needs of adult PLHIV in care in Eastern Estonia, we 
conducted a mixed methods study, applying a theory- and evidence-based health 
promotion intervention development and evaluation framework – Intervention 
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Mapping (IM) (Kok et al. 2004, Bartholomew et al. 2006). The IM protocol 
consisted of 6 steps: (1) target group needs assessment, (2) proximal program 
objectives identification, (3) intervention theory and strategy selection, and 
program (4) development, (5) implementation and (6) evaluation.  
Methodologically each step in IM drew from and built upon the following 
data sources and procedures (summarized in Table 1 in PAPER I):  
(i) Literature review through electronic information space (MEDLINE, 
Cochrane CENTRAL, ISI-Web of Science) search on key domains: 
HAART, medication adherence/patient complicance, behavior theory/ 
methods, intervention and program development; from 2000 to 2009. 
(ii) Individual data evaluation and team discussions (at meetings and tele-
conferences) amongst the multidisciplinary international research team, 
consisting of 2 public health researchers, experienced in HIV/IDU, medical 
doctors (University of Tartu, Estonia); a researcher/instructor in health 
behavior change, experienced in ART adherence, a psychologist (Uni-
versity of Connecticut, USA); 2 nurse counselors (Ida-Viru Central 
Hospital, Estonia), supporting the researchers in adapting the intervention 
to local conditions. 
(iii) Formative research to obtain data on local ART adherence determinants 
in Ida-Viru County: interviews with 4 medical service providers, held by 
research team member (medical doctor, University of Tartu, Estonia); two 
focus-group discussions with ART-experienced HIV-positive adults, held 
by a sociologist (University of Tartu, Estonia).  
 
Previously published methods for intervention development were followed or 
adapted (Kok et al. 2004, Perez-Rodrigo et al. 2005, Bartholomew et al. 2006, 
Kok et al. 2006, Wolfers et al. 2007, Côté et al. 2008).  
 
PAPER II 
For implementation and evaluation of the efficacy of the developed intervention 
(the final steps in the IM framework), a small-scale feasibility randomized 
controlled trial (RCT) was conducted at Ida-Viru Central Hospital in 2010–
2011 (with 1:1 randomization, comparing the developed ART adherence inter-
vention to usual care with 12 months follow-up). Analysis of baseline data from 
this study sample of 161 (11 pilot and 150 randomized) consecutive consenting 
patients presenting for routine HIV clinical care visits at the hospital between 
July and December 2010 is presented in this dissertation.  
At the time of the study, Ida-Viru Central Hospital provided HIV care to 
651 patients, with 372 of them receiving ART (EHIF 2011). Convenience 
sampling was used to recruit the study subjects. Patients were included when at 
least 18 years of age, able to read/write in Estonian or Russian, and on ART. A 
structured interviewer-delivered questionnaire was administered by a trained 
nurse, taking approximately 45–60 minutes to complete. These interviews were 
conducted in a private location in the clinic following the participant’s medical 
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visit. Medical data were abstracted from clinical records by the study physicians 
using a standardized data abstraction form.  
In patient interviews, adherence was assessed via a 3-day recall of doses 
missed (Chesney et al. 2000). Rates of adherence were calculated as the pro-
portion of total doses taken in full as prescribed over total doses prescribed (in 
past 3 days). Data collected from the interview also included participants’ socio-
demographic and health status characteristics, self-reported health insurance 
status as a proxy for access to healthcare, HIV testing and healthcare (including 
ART) utilization history, knowledge and beliefs about ART, and history of risk 
behaviors (sexual and substance abuse). Data abstracted from clinical record 
included the ART regimen prescribed, duration of ART, co-infections such as 
hepatitis C, CD4 cell counts, and HIV RNA level (viral load) with sensitivity of 
50 copies/ml.  
From all participants in the adherence support intervention arm of the study 
also data on facilitators and barriers to adherence were collected during 
adherence counseling session(s) (PAPER I). 
Participants (PLHIV) in the adherence research project received a super-




4.1.2. Data analysis  
PAPER I 
Coding data were descriptive and thematic (Miles & Huberman 1994). Inter-
views in focus groups were coded initially for emerging core descriptive content, 
and further refined in an iterative process of data coding, charting and inter-
pretation. Data were processed by hand. Transcripts of both interviews were 
summarized in a separate file on the computer with participants only identified 
by age and sex. 
 
PAPER II 
For the analysis presented in PAPER II, baseline (cross-sectional) data of the 
pilot RCT were used. In statistical analysis nonadherence was selected as the 
primary outcome (dichotomized, with the cut-off of < 100% as nonadherent). 
Socio-demographic, substance abuse, and other factors were compared between 
the adherent and the nonadherent group. Correlates of adherence were explored 
using the Fisher’s exact test and Wilcoxon rank sum test; crude odds ratios of 
nonadherence were calculated. Logistic regression was used to estimate 
adjusted odds ratios. Factors associated with adherence in bivariate analyses at 
significance level of 0.1 or lower (and not considered an outcome of adherence) 
were adjusted for. Generalized variance inflation factor was calculated for all 




4.2. Systematic review of interventions supporting  
safe sexual behavior among HIV-positive adults  
receiving HIV medical care (PAPER III) 
4.2.1. Study search and selection 
Studies were selected for the systematic review (PAPER III) based on study 
design and implementation criteria of effective behavioral interventions reducing 
HIV sexual risk taking among PLHIV, identified in previous research (Crepaz 
et al. 2006), and defined by the CDC HIV/AIDS Prevention Research Synthesis 
Project (CDC 2016b).  
We included randomized and quasi-randomized controlled trials imple-
menting individual-level behavioral interventions specifically designed for 
sexual risk behavior reduction (in comparison to ‘no such intervention’) to be 
delivered in healthcare settings by HIV care providers to adult PLHIV in care.  
The outcome of interest was sexual risk behavior reduction, based on at 
least one behavioral measure (number of sexual partners, number of condomless 
sexual acts or condom use consistency) or one biological measure (sexually 
transmitted infection, hepatitis B acquisition). The studies had to assess the 
outcome(s) after at least 3 months (90 days) from intervention initiation. 
Specific search terms were developed for the following concepts: HIV/AIDS, 
sexual (risk) behavior, behavioral intervention, and (quasi)randomized study 
design. Between February 21 and 23, 2014 relevant studies from 1981 (the year 
AIDS was first reported in the world) (CDC 1981) to 2013 (year end) with no 
language or publication status restrictions were searched from: 
(i) electronic biomedical literature databases: MEDLINE (PubMed), MEDLINE 
(Ovid), Embase (Ovid), the Cochrane Central Register of Controlled Trials 
(CENTRAL) (Cochrane Library), PsycINFO (EBSCOhost), and CINAHL 
(EBSCOhost); 
(ii) abstracts of HIV/AIDS conferences recommended by the Cochrane Review 
Group on HIV/AIDS (Cochrane Review Group on HIV/AIDS 2014): 
International AIDS Conference (AIDS), International AIDS Society Con-
ference on HIV Pathogenesis, Treatment and Prevention (IAS), and Con-
ference on Retroviruses and Opportunistic Infections (CROI). 
Also references of the retrieved publications were screened for additional 
reports of same studies and other relevant studies.  
All the search, selection, data abstraction, and evaluation methods were 
standardized, and applied independently by two reviewers at each stage. Cita-
tions retrieved from electronic databases were merged and duplicates deleted, 
then screened by title and abstract. Full texts of all potentially eligible publi-
cations were read to assess the study design, types of participants, interventions, 
and outcome measures. Agreement between reviewers was measured with 
Cohen’s kappa (Higgins & Green 2011), and studies were promoted to the next 
phase after inclusion consensus was reached. Characteristics of each study that 
met the review inclusion criteria were extracted.  
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4.2.2. Study quality and results analysis 
Methodological quality of studies included in the review was assessed according 
to the recommendations of the Cochrane Handbook of Systematic Reviews of 
Interventions (Higgins & Green 2011). Potential selection bias (random sequence 
generation, allocation concealment), performance bias (blinding of participants 
and study personnel), detection bias (blinding of outcome assessment), attrition 
bias (intention to treat analysis, outcome data completeness and how incomplete 
data were dealt with), reporting bias (selective outcome reporting) and other 
biases, if applicable, were evaluated. Risk of bias was categorized as either ‘low’, 
‘high’ or ‘unclear’. At any stage of the evaluation all disagreements and uncer-
tainties were discussed, and consensus was reached between the two reviewers. 
The results of the assessment were organized and presented in a ‘risk of bias’ 
table.  
Results of the original studies included in the review were synthesized 
qualitatively. In studies with interventions targeting several transmission risk 
behaviors only the sexual risk behavior component was assessed, and in studies 
with multiple follow-ups only data from the last were considered. Authors of all 
the studies (included in the review) were contacted to clarify the results and 
request data not provided in the publication(s). For count data (e.g., number of 
sexual partners or unprotected sexual acts) means with standard deviations (SDs) 
were considered. For dichotomous outcomes (e.g., condom use consistency: 
always/not always using a condom) the effect sizes [odds ratios (ORs) with 95% 
confidence intervals (CIs)] in comparing the intervention and control groups were 
considered. The results of the original studies were organized and presented in a 
summary of findings table.  
Systematic review conclusions were drawn, considering the intervention 
effect magnitude and methodological quality in the original studies. 
 
 
4.3. Cross-sectional review of people living with HIV 
engagement in HIV care in Estonia (PAPER IV) 
4.3.1. Study data sources and operational definitions 
In the cross-sectional review (PAPER IV) national level HIV data, applying the 
HIV care cascade model, and the metrics developed by CDC (CDC 2011) and 
the Institute of Medicine (IOM) (Ford & Spicer 2012), were synthesized. The 
number of people (1) living with HIV, (2) diagnosed with HIV, (3) linked to 
HIV care, (4) retained in HIV care, (5) on ART, and (6) with suppressed viral 
load (HIV RNA < 200 copies/mL) in Estonia in 2013 was assessed. In addition to 
the 6 cascade steps, we also evaluated the timing of initiation of HIV care and 
PLHIV health state (based on CD4 cell count) at reaching specialized HIV care, 
and at ART initiation.  
The number of people estimated to live with HIV in Estonia in 2013 was 
based on the UNAIDS Spectrum estimate (AIDSinfo 2014). For the number of 
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PLHIV at the next steps of the cascade, data were obtained from local country-
level sources – the Estonian Health Board (EHB), the Estonian Health 
Insurance Fund (EHIF), the Estonian HIV-Positive Patients Database (E-HIV), 
and the Estonian Causes of Death Registry (ECDR), characterized in Tabel 1. 
 
To calculate an indicator for each step in the HIV care cascade, the most rele-
vant of the data sources was/were selected, and a timeframe (period) for data to 




Table 1. Overview of study data sources, Estonia, 2013 
Data source Characteristics 
Estonian Health 
Board (EHB) 
Agency of the Estonian Ministry of Social Affairs (EMSA) 
Responsible for passive surveillance of communicable diseases 
(including HIV), hence recording all newly diagnosed 




Institution, operating within the administration area of EMSA as 
an independent legal body 
Core purchaser of healthcare services for the compulsory health 
insurance system in Estonia, hence possessing healthcare 
utilization data, covering all medical services and service costs 
(except ART medication costs) provided to PLHIV; nationwide 
coverage 
An identification code is assigned to each individual, enabling 
longitudinal tracking of care provided to individuals without 




Database, operated by the Estonian Society for Infectious 
Diseases 
Contains detailed, longitudinal demographic and clinical data of 
PLHIV in Estonia, including date of HIV confirmation, mode of 
HIV acquisition and course of HIV care (with dates of clinical 
appointments, ART provision, dates and results of CD4 cell 
counts, viral load values), and concomitant diseases (Soodla et al. 
2015)  
Data from consenting PLHIV in HIV medical care, recorded 
since April 2009 (when the database was established); also 
includes some retrospective data 
Estonian Causes of 
Death Registry 
(ECDR) 
Registry, operated by the Estonian National Institute for Health 
Development (NIHD). 
Collects data on all cases of death (including the cause); nation-
wide coverage  
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a First HIV case in Estonia was diagnosed in 1988 
b End of our study period  
c Earliest date appearing on a HIV-related medical service reimbursement claim (the date of “opening” 
the medical service account) in the EHIF electronic database since its inception 
 d To evaluate the situation in 2013, data from this 12 months period were used  
 
Table 2. Operational definitions and data (with time and source) for the six steps of the 
cascade of HIV care in Estonia, 2013 
 Operational definition,  












Aggregated number of confirmed HIV-positive tests 
(individuals) minus the aggregated number of deaths (AIDS 
deaths, specified proportion of illicit drug overdose related 
deaths) 
Time period: 1.01.1988a– 31.08.2013b 
Estonian Health 
Board (EHB);  







The number of individuals with at least one HIV-related 
healthcare visit, based on individual anonymized 
reimbursement claims of HIV-related healthcare services: 
visit dates, medical services provided to PLHIV (with 
dates), healthcare providers issuing the claims 






HIV care  
 
  
The number of individuals with 2 or more HIV-related 
healthcare visits (at least 3 months apart) within the past 12 
months  




On ART Step 1: The proportion of individuals on ART among those 
retained in care, based on individual anonymized data from 
E-HIV: HIV verification time, ART initiation time, dates 
and results of CD4 cell and HIV RNA tests, dates of other 
medical services provided to and visits of PLHIV 
Step 2: The number of individuals on ART among those 
retained in care according to EHIF, when applying the 
proportion obtained in Step 1 to individuals retained in care 
according to EHIF  










Step 1: The proportion of individuals on ART with the 
most recent (within the past 12 months) HIV RNA < 200 
copies/mL, based on individual anonymized data from 
Step 2: The number of individuals virally suppressed 
according to EHIF, when applying the proportion obtained 
in Step 1 to individuals on ART according to EHIF  









For the timeliness of PLHIV accessing HIV care, we looked at individuals 
newly diagnosed with HIV in past 12 months and calculated the time from HIV 
diagnosis to linkage to HIV medical care for each patient. For this analysis, 
linkage to care was defined as the first visit to an infectious disease doctor 
(qualified to follow and treat people infected with HIV in Estonia) when a CD4 
cell count and/or HIV RNA level was measured. Linkage to HIV medical care 
was considered timely when this first visit took place within 90 days of HIV 
verification (Ford & Spicer 2012). We also looked at E-HIV data on patients’ 
CD4 cell counts obtained during the first HIV medical visit (as defined above) 
and at ART intiation. 
 
 
4.3.2. Data management 
The number of PLHIV estimated to live in Estonia in the year of study 
(according to UNAIDS) was used as a denominator for calculating indicators 
for all the subsequent steps in the HIV care cascade. Carefully constructed case-
finding algorithms were applied to identify individuals from local health 
administrative databases. When the most applicable data source did not have 
nationwide coverage, the result was extrapolated to another source with national 
coverage to obtain a population-based estimate.  
Information bias in data sources was mitigated by detailed data review at 
face-to-face meetings of the research team, and consultations with HIV medical 
care providers and community partners. We compiled cross-comparisons of the 
data and discussed any discrepancies and, if necessary, obtained additional data 
and consultations until consensus was reached. 
 
 
4.4. Ethical considerations 
Until HIV cure will be developed, complex measures have to be taken to control 
the virus. Selecting the most effective evidence based measures includes research 
among people living with HIV (PLHIV). As HIV infection still carries more 
stigma than most other diseases and health conditions, special precautions have 
to be taken in research projects involving PLHIV (Rennie & Sugarman 2010, 
UNAIDS/WHO 2012, Lo et al. 2013).  
For research on ART adherence among PLHIV presented in this disser-
tation ethical review took place at the Ethics Review Committee on Human 
Research of the University of Tartu, Estonia. The research presented in Papers I 
and II was conducted at infectious diseases clinics in Kohtla-Järve and Tallinn, 
and recruited HIV-positive patients as study subjects (ERC approvals no 190T-
17, 2010 February 22; 195/M-25, 2010 August 30). 




(i) Exclusion of intoxicated persons: Intoxicated persons were not eligible 
for the study by virtue of inability to provide true informed consent. The 
interviewers queried potential subjects on their use of drugs prior to 
informed consent procedures, and used their observation and judgment to 
determine whether the potential subject was not eligible due to intoxi-
cation and whether the interview underway needed to be ended.  
(ii) Inclusion of women: Our recruitment procedures did not in any way 
discriminate against women. 
(iii) Inclusion of minors: Recruitment was limited to people aged 18 and 
older. 
 
Information was obtained from interviews and abstracted from clinical records. 
Data collection in qualitative interviews was undertaken by experienced and 
specially trained researchers. Data collection from the clinic population (stan-
dardized questionnaire based interviews, clinical record abstracts) was under-
taken by study participants’ routine HIV care providers and added to routine 
clinic visits. Each participant was assigned a unique study identification (ID) 
number, and all study participants’ data were identified only by the study ID 
numbers (with identification information known only to the care provider). The 
research team at the University of Tartu did not collect (qualitative research: 
focus groups) or receive (clinical study) any data that would have enabled to 
identify the study participants.  
 
The primary risks to clinical study participants forseen were stress from loss of 
privacy and the psychological risks of disclosing personal alcohol/drug use and 
sexual behavior information. The approaches in place to protect against these 
risks were the following: 
Recruitment and informed consent: Potential participants were informed 
that their participation in the study was strictly voluntary and that they were free 
to withdraw from the study at any time. Following a careful explanation of the 
study, eligible patients were given the consent form to read or, if necessary, the 
consent form was read to the patient by project staff (in Estonian or Russian). 
For participation in the study a written consent was secured. 
The psychological risk: The content of the interviews contained sensitive 
information such as the possibility of developing a potentially fatal illness and 
engaging in highly stigmatized behaviors. Such content could prove upsetting to 
some subjects. In order to guard against the possibility of extreme distress 
subjects were informed before the interview that they were free to decline to 
answer any questions or to stop the interview at any time should they feel anxious 
or uncomfortable in answering. We must emphasize, however, that based on all 
of our previous research, we considered the likelihood of extreme personal 
distress in reaction to the content of the questions to be very low.  
Protection of individual privacy: A private room was used for study proce-
dures and conducting the interview.  
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Protection of confidential information: All study data including behavioral 
and clinical information were kept in a confidential manner and concerted 
efforts were made to ensure confidentiality. Specifically: (1) all files were in 
locked areas, (2) patient identification information was not available to the 
research team at the University of Tartu, (3) study staff was trained on confi-
dentiality issues (no discussions on individual respondents with anyone else, 
even in general terms; holding interview in private with only the respondent and 
the interviewer present; careful following of standard study procedures).  
 
While not dismissing the abovementioned risks, we suggested the potential 
benefits, including ART adherence counseling and development of HIV pre-
vention programs, substantially outweighed the risks to the participants. There 
was an opportunity to address important research questions that could not have 
been easily or readily addressed elsewhere. Effective interventions supporting 
ART adherence presume systematic development, and should be built on 
mapping the situation (e.g., ART adherence level, main barriers and facilitators) 
and the target population (i.e., PLHIV initiating or receiving ART) values and 
needs. We saw the lessons learnt from the project being potentially important 
and results applicable for a wider community in Europe, especially in 
neighbouring countries with similar socio-economic history that have witnessed 
similar HIV epidemics.  
 
The research undertaken and presented in PAPERS III and IV did not warrant 
research ethics board review, as was based on published research or aggregated 
surveillance and administrative data. The research in PAPER IV was in agree-





5.1. Antiretroviral therapy adherence and factors 
associated with it among HIV-positive adults receiving  
HIV medical care in Estonia (PAPER I, PAPER II) 
PAPER I 
In the ART adherence support intevention development study adult ART-
experienced HIV-positive focus groups participants (n = 14, five female, aged 
18–50) identified lack of time, drug/alcohol abuse, side-effects of ARV drugs, 
and considering ART unnecessary as the main individual barriers to ART 
adherence. Whereas, support from a family member or friend, desire to remain 
healthy to raise a child, tools or methods for organizing pill-taking or linking it 
to other routine daily activities were noted to facilitate adherence.  
The focus groups interviews also revealed another facet of treatment 
adherence – gaps in patients’ ART adherence knowledge. While PLHIV were 
aware that not taking their pills as prescribed would lead to resistance, they did 
not fully understand how would it develop and how missing one pill or a few 
every once in a while could contribute to this. Misconceptions related to ART 
included defining nonadherence as not taking medication for a long period – a 
month or two, as well as uncertainty about the actual function and effects of 
ARV drugs were detected. The importance of taking every pill was especially 
hard to recognize by patients who did not feel ill, but experienced medication 
side effects. In some patients adherence had eroded over time (before the inter-
vention) when HIV-related symptoms diminished, yet medication side-effects 
increased.  
Adherence determinants were also studied among patients, randomized to 
the intervention arm of the ART adherence support intervention (developed for 
Estonia) feasibility testing trial. In this sample (n = 75, 2/3 male; median age 
32; predominantly unemployed; 65% reporting IDU related HIV acquisition, 
median of 6 years living with HIV, and 2 years on ART; and 7% acknowledging 
missing at least 1 pill in past 3 days), the main barriers to ART adherence iden-
tified were in good agreement with the information obtained in the focus-group 
interviews (described above). More than half of patients in the RCT inter-
vention arm identified ‘social support (including having a child)’ and ‘future 
perspectives (desire to stay alive/healthy)’ (59% and 55%, respectively), and 29% 
‘routinization of pill-taking (a well-establisehd method)’ as facilitators to staying 
adherent to the treatment prescribed. ‘Medication side effects’, ‘irregular, intensive 
personal or working-life’ and ‘alcohol/illicit drug abuse’ were the barriers most 
frequently reported (44%, 27% and 13%, respectively). Overall, only 3% of 






Among the 161 study participants at Ida-Viru Central Hospital at study baseline 
in 2010 a small subset (n = 17) lacked experience with ART as were just starting 
the therapy, and were thus excluded from further analysis. Participants retained 
for the analysis (n = 144) were aged 19 to 77 years (mean 33.8, SD 8.23), and 
55% (79) male. Over half of them lived in a relationship (26.6% married, and 
28.7% living with a sexual partner). Two-thirds (70%) of participants had com-
pleted more than 9 years of education. Most (73%) were unemployed and lived 
on social benefits (53%) or income from relatives/partner (20%). However, vast 
majority (91%) were covered by Estonian state health insurance. Based on self-
reported time of testing positive for HIV, on average these 144 patients had 
been aware of their HIV seropositive status for 5.6 years (SD 3.49). Two-thirds 
(63%) had acquired HIV through IDU (82.9% of men, 39.1% of women). One-
third also reported illicit drug use within the preceding year, and almost ¼ 
scored as having increased likelihood of hazardous and harmful alcohol use. 
One-third also reported signs of clinically significant depression. The study 
participants had been on ART for an average 1.5 years (SD 1.5). While 88% 
(95% CI 81–92%) of participants reported 100% adherence over the past 3 days, 
viral load was undetectable for only 56% (n = 80). Although the mean CD4 cell 
count was 355 cells/mm3 (SD 225 cells/mm3), a quarter of the sample (26%) 
had a CD4 cell count below 200 cells/mm3.  
Bivariate analysis showed that ART nonadherence was not associated with 
assessed concurrent morbidities (depression, alcohol, and drug use) or ART 
regimen factors (number of pills and dosing frequency). No differences were 
found in adherence between those reporting having ever injected drugs and 
those not, and between PWID currently in opioid substitution therapy or not. 
Although less than perfect adherence was reported more commonly among drug 
users compared to nonusers, the difference was not statistically significant.  
Multivariate analysis, when adjusting for insurance status and self-rated 
health, showed that study participants who exhibited greater concerns about 
perceived negative consequences of taking ART had five times the odds of being 
nonadherent than those with lower concerns [adjusted odds ratio (AOR) 4.8, 
95% CI 1.2–34.0]. Nonadherence was also associated with average (versus 
good/very good) self-reported health status (AOR 4.6, 95% CI 1.2–31.4). While 
already in bivariate analysis study participants with detectable viral load were 
more likely to be nonadherent (OR 5.3, 95% CI 1.5–23.2), it also remained 
significantly associated with nonadherence in multivariate analysis (AOR 3.9 
95% CI 1.3–14.7). However, viral load should rather be interpreted as an out-




5.2. A feasible evidence-based antiretroviral therapy 
adherence support program tailored to HIV-positive adults 
receiving HIV medical care in Estonia (PAPER I) 
In addition to our findings from the ART adherence support intervention devel-
opment study focus group interviews among ART-experienced adult PLHIV 
(described above in paragraph 5.1.), interviews with HIV medical care providers 
revealed inconsistencies in how ART adherence was discussed with patients as 
well as how frequently nonadherence was identified – no standard protocol was 
followed and most discussions occurred early in the course of prescribing ART. 
It also appeared that later in the treatment nonadherence was reported by patients 
infrequently, and doctors tended to “discover” problems with adherence only 
from poorly controlled viremia, drops in CD4 cell count, or failure to pick up 
medication refills. 
Findings from the first step in developing the adherence support program i.e., 
the gaps in patient information, motivation, social support, and skills, combined 
with an understanding that the current standard of support for adherence did not 
involve a strong patient-education component or open discussions concerning 
challenges (or successes) with adherence, guided the following identification of 
program objectives and development. 
Secondly a guide, informed by all data sources (focus groups, research team, 
literature) was developed to map objectives for the intervention program 
(Figure 1 in PAPER I). Two core sets of behaviors – ‘integrating the treatment 
plan into one’s daily routine’ and ‘handling situations in which ART is difficult 
to take’, were selected for promotion. These were the topics that patients could 
discuss during the intervention without having to disclose whether drug doses 
were actually missed. 
At the third step in developing the intervention, the Information–Moti-
vation–Behavioral Skills (IMB) theory of ART adherence (Fisher et al. 2006, 
Munro et al. 2007, Fisher et al. 2008) was chosen to build on. Further, based on 
the IMB model and our initial work, patient knowledge, motivation, and skills 
were identified as the critical change objectives. For the intervention approach, 
the Next Step Counseling (NSC) to ART adherence was selected and adapted. 
NSC, previously used in HIV pre-exposure chemoprophylaxis trials (Amico et 
al. 2010, Grant et al. 2010), involved brief and flexible guided discussions 
targeting identification of adherence-related needs and strategizing on them, 
using motivational interviewing techniques.  
At the fourth step, an intervention program entitled “Situated Optimal 
Adherence Intervention (sOAI) Estonia”, comprising of 3 one-on-one sessions 
with a trained study nurse, was developed (Figure 2).  
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Figure 2. Antiretroviral Therapy Adherence Promotion Session Flow in Situated 
Optimal Adherence Intervention Estonia (sOAI Estonia). 
 
 
The frequency of sessions (approximately 3 months apart) was chosen to 
distribute the intervention over an optimal time period, yet minimizing extra 
visits by linking the counseling sessions to patients’ regular medication refill 
and other clinic visits. The first intervention session included an explanation of 
the study and the role of nurse as a collaborator with the participant; going 
through an educational flipchart on HIV and ARV drugs and eliciting patient 
reactions to this. A standardized flipchart, using figurative metaphors to promote 
understanding and personalized knowledge of HIV in the body and how ARV 
drugs can protect the immune system, was created specifically for the sOAI 
Estonia program (Figure 3 in PAPER I). After eliciting participant reactions to 
the flip chart, the nurse initiated a NSC discussion (Figure 4 in PAPER I). For 
assessment of information obtained from the patient during counseling, Neutral 
Assessment (NA) strategies (Amico et al. 2010) were adopted to promote parti-
cipants’ sense of candor and comfort in having open discussions about ART 
adherence. Intervention Sessions 2 and 3 involved a brief check on any questions 
from the previous session(s), and implementation of the NSC discussion (Figure 
2). Each NSC discussion concluded with identifying something the participant 
would try to help him/her with adherence between the clinic visits. At the 
following session, the nurse asked the participant how this had gone and then 
discussed the current experiences with ART and what the participant now felt 
would be most helpful to integrate daily ART into his/her life.  
The fifth step in developing the intervention program resulted in imple-
menting the sOAI Estonia program in Ida-Viru Central Hospital. At this stage 
the intervention nurse and interviewer were trained in study procedures and 
methods, and a study manual on NSC and NA, a one page NSC counseling record 
form, and a standard questionnaire for patient interviews including adherence 
 


















NSC Strategy  selected 
Increase knowledge and understanding 
Foster personal and social motivation 
Enhance engagement and agency in care 
Build strategies 
Check in on lingering questions/concerns 
Offer review 
 
NSC New or existing strategy selected 
Sustain/increase knowledge and understanding 
Promote modelling of problem solving  
Foster personal and social motivation 
Enhance engagement and agency in care 
Build strategies 
Reinforce maintenance of effective strategies 
Check in on lingering questions/concerns 
Provide brief review of flipchart 
 
NSC Closure/termination discussion 
Sustain progress 
Reinforce positive use of HIV care 
Promote continued problem solving 
Foster understanding, personal and social 
motivation and skills 


























assessment were employed to standardize and monitor the implementation. 
Further methodological and practical intervention implementation support was 
provided to the hospital-based study team at least once a month during whole 
study period in regular on-site meetings with project manager (a researcher 
from the University of Tartu).  
Lastly, as the sixth step in developing the intervention program in 2010–
2011, a RCT to compare sOAI Estonia to regular counseling in a convenience 
sample of 150 consecutive adult patients attending the infectious diseases 
department at Ida-Viru Central Hospital, and receiving or initiating ART, was 
undertaken. Treatment adherence level, measured by patient 3-day recall self-
report and hospital medication dispensing records at baseline, and at 6 and 12 
months, was chosen as the primary outcome. In addition, data on HIV RNA 
level and CD4 cell count were evaluated at same time points. As part of the 
intervention program evaluation alongside with the RCT, also the feasibility, 
acceptability, and fidelity of sOAI Estonia were reviewed. Whereas for patients 
the brief counseling sessions (in the intervention arm) were added to their 
routine clinic visits, also the hospital personnel did not complain about exces-
sive workload during the study, but reported better understanding of their 
patients through enhanced communication. The nurse counselors also reported 
feeling rewarded by the “Aha!” effect their explanations about HIV and ARV 
drugs generated in many counseled patients.  
 
 
5.3. Systematically indentified and synthesized evidence 
for supporting safe sexual behavior among HIV-positive 
adults receiving HIV medical care in Estonia (PAPER III) 
As a result of rigorous publication search with terms addressing all the main 
concepts of the review question, 950 citations from electronic biomedical 
literature databases and 34 abstracts from conference proceedings from 1981 to 
2013 were retrieved. After systematic assessment and evaluation, the originally 
retrieved body of evidence on behavioral interventions for adult PLHIV, pro-
vided on individual level by caregivers in HIV care settings, to determine their 
efficacy in reducing sexual risk behavior was limited to 5 randomized studies 
(The Healthy Living Project Team 2007, Cornman et al. 2008, Gilbert et al. 
2008, Safren et al. 2013, Kurth et al. 2014*)1(Figure 1 in PAPER III).  
Interventions in the studies included in the review had been conducted in 
real life conditions, yet differed greatly in duration and intensity – from brief (15-
minute) sessions a few months apart (Cornman et al. 2008) to fifteen 90-minute 
sessions in a year (The Healthy Living Project Team 2007). Participants in all 
                                                            
* Remark: The Kurth et al. study here in text and list of references was published in 2014. However, at 
the time of publication search for the systematic review an earlier (electronic) version was retrieved, 
and thus the study still fitted into the pre-defined for the review time frame for publication search, 
ending with December 31, 2013. 
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the studies had been both men and women, except in one study among men who 
have sex with men (MSM), and included different ethnic groups. All studies 
had included main HIV risk groups (PWID, MSM), based on HIV acquisition 
mode or reported risk-behavior. The risky sexual behavior of participants varied 
greatly, because two studies (The Healthy Living Project Team 2007, Safren et 
al. 2013) had only recruited people reporting prior sexual acts not protected 
with condom (in past 3 months), while others had no precondition of recent 
sexual activity. Overall, the quality of evidence in the studies included was 
relatively low, even when ignoring blinding of participants and providers which 
is not possible in behavioral intervention studies. Only two of the five studies 
had low risk of bias (Safren et al. 2013, Kurth et al. 2014).  
No evidence was available about the effect of sexual risk reduction inter-
vention(s) on the more objective biological measures of sexual risk behavior, as 
none of the studies included in the review measured sexually transmitted infec-
tion (STI) and/or hepatitis B acquisition. Although all the predefined (for the 
review) behavioral effect measures were likely recorded in all of the 5 selected 
studies, judging from the list of characteristics reported for study participants at 
baseline or described in other parts of the publications, filling in the data gaps 
(by contacting the corresponding authors of the publications) failed. Thus, the 
intervention effect analysis for each of the outcome measures was based on less 
than 5 studies, reducing the ability to draw extensive conclusions on the effect 
of the intervention(s). Three different quality and size studies evaluated the 
intervention effect on the number of condomless sexual acts, yet failed to 
support the interventions (The Healthy Living Project Team 2007, Cornman et 
al. 2008, Safren et al. 2013).  
The following results supporting sexual risk reduction interventions (Table 3), 
based on the selected for the review effect measures, were obtained from studies 
by: 
(i) Gilbert and colleagues, where a statistically significant difference between 
the study arms in reduction in the mean number of casual sex partners 
(among those who completed the study) was observed [–2.7 (SD 8.4) in 
the intervention group versus –0.6 (SD 5.6) in the comparison group; 
p = 0.042] (Gilbert et al. 2008);  
(ii) Kurth and colleagues, where sexual risk behavior change was assessed 
through condom use consistency, and the odds of not always using a 
condom (a dichotomized outcome) in HIV transmission risk acts was 
lower in the intervention group than in the control group (OR = 0.46, 95% 
CI 0.25–0.84, p = 0.012) (Kurth et al. 2014);  
(iii) The Healthy Living Project team, where the difference between the mean 
number of sexual transmission risk acts was not significant in the study 
groups at study end (month 25), yet had been statistically significant 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Still, the evidence should be interpreted with some caution due to the relatively 
low quality of the Gilbert study (Gilbert et al. 2008), and one other study (in 
addition to the one conducted by Kurth and colleagues) reporting on condom 




5.4. People living with HIV engagement in HIV care  
in Estonia (PAPER IV) 
According to UNAIDS most recent (when conducting the study) estimation 
there were 8 628 (6 941–10 783) PLHIV in Estonia in 2013 (AIDSinfo 2014). A 
total of 8 605 new HIV cases had been registered in Estonia from 1988 to 
31.08.2013 (the end of our study period) according to the Estonian Health Board 
(EHB 2013). However, taking into account the potential multiple registration of 
new cases until 2009, and the AIDS and IDU related deaths among PLHIV over 
the years, we calculated that 5 077 to 7 424, mean 6 251 individuals diagnosed 
with HIV had been living in Estonia at our study end. Hence, altogether 72% 
(47–100%) of the 8 628 PLHIV estimated to live in Estonia in 2013 had been 
diagnosed with HIV.  
Since the inception of the Estonian Health Insurance Fund (EHIF) electronic 
database of medical claims in 2000, altogether 4 375 HIV-positive patients (alive 
by the end of our study) had received at least one HIV-related medical service 
by designated HIV medical care provider(s). According to these data, 51% (41–
63%) of the 8 628 HIV-positive people estimated to live in Estonia in 2013 
were considered to have ever accessed i.e., been linked to HIV medical care (by 
our study end). 
In the past year (01.09.2012–31.08.2013) according to EHIF 1 855 PLHIV 
had received HIV-related healthcare at least twice, and at least 3 months apart. 
This translates into 21% (17–27%) of the total 8 628 HIV-positive people esti-
mated to live in Estonia in 2013 being retained in HIV care in 2013. 
Based on data obtained from the Estonian HIV-Positive Patients Database 
(E-HIV), 82% of PLHIV considered retained in care (1 022 of 1 250) were also 
receiving ART. Applying this proportion to EHIF data, an estimated 1 521 of 
PLHIV retained in care according to EHIF in 2013 could also have received 
ART. Altogether, this translates into 18% (14–22%) of the 8 628 HIV-positive 
people estimated to live in Estonia in 2013 receiving ART in 2013. 
E-HIV included at least one viral load test result for the study period for 
1 021 of the 1 022 PLHIV continuously in care and on ART. Of these, 70% 
(712) had achieved viral suppression (HIV RNA < 200 copies/mL) in their most 
recent test. Applying this proportion to EHIF data, we estimated that 1 065 of 
PLHIV continuously in care and on ART according to EHIF had achieved viral 
suppression. This would translate into 12% (10–15%) of all 8 628 HIV-positive 
people estimated to live in Estonia in 2013 having achieved viral suppression. 
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When looking at the timing of PLHIV linkage to HIV care, according to  
E-HIV 111 individuals had been newly diagnosed with HIV during the study 
period (1.09.2012–31.08.2013). Excluding patients with missing data, and 
allowing all patients the optimal 90 days to reach HIV care, we found that 86% 
of those newly diagnosed (74 patients of 86) had accessed HIV care within 90 
days of testing positive for HIV. At the same time, regardless of how long it had 
taken people diagnosed with HIV to access HIV medical care, more than half 
(62%) of those registered during the past year (n = 90), had had a CD4 cell 




6.1. People living with HIV engagement  
in HIV care in Estonia 
The HIV care cascade model allows to map PLHIV at certain steps in the con-
tinuum of care and define the proportion that has achieved the ultimate goal of 
HIV care – viral suppression. This should translate into understanding where 
interventions to improve coverage with care are needed foremost (Medland et 
al. 2015). In Estonia, as in other countries where engagement in HIV care has 
been evaluated, PLHIV were “lost” at each step of care, and in 2013 only 12% 
(10–15%) of all the 8 628 (6 941–10 783) HIV-positive people estimated to live 
in Estonia had achieved viral suppression. Engagement in care at the different 
steps of the HIV care cascade in Estonia in 2013 most resembled that recently 
described in Georgia (Raymond et al. 2014), a country with similar politico-
economic history and HIV epidemic, driven by injection drug use until 2011 
(UNAIDS 2014d). Regarding the ultimate goal for PLHIV in HIV care (i.e., 
viral suppression), large disparities in the world, apparent also within Europe, 
have been recently described: while in Western European countries over 50% of 
PLHIV were virally suppressed, in Eastern European countries this proportion 
remained below 20% (Levi et al. 2015).  
According to our study, in Estonia the main gaps in HIV care in 2013 were: 
(i) about ¼ of the 8 628 persons estimated to live with HIV had not been 
diagnosed with HIV;  
(ii) another ¼, although aware of their HIV-positive serostatus, had not 
accessed HIV medical care;  
(iii) over ½ of PLHIV, having accessed HIV medical care from an infectious 
disease specialist after diagnosis, were not retained in care.  
 
With a quarter of PLHIV unaware of their HIV status, HIV testing appeared to be 
the primary bottleneck in reaching the UNAIDS HIV care coverage targets in 
Estonia. Also the issue of PLHIV not accessing applicable care after diagnosis 
was likely related to testing i.e., the current counseling and referral to care pro-
cedures and practices (WHO Regional Office for Europe 2014). Our research 
also revealed that even for PHIV linked to specialized care within 3 months of 
the diagnosis, this timely linkage often occurred too late in the course of the 
disease, given the low CD4 cell counts of PLHIV at initiation of specialist care 
(62% with ≤ 350 cells/mm3). Late linkage to care seemed to be related to 
delayed testing for HIV, supporting the need to evaluate the current HIV testing 
policies in Estonia to better reach all key settings and populations with effective 
services (WHO Regional Office for Europe 2014, UNAIDS 2015b). Whereas 
according to national recommendations, in 2013 HIV testing was mandatory for 
blood and organ donors (and in some cases for people in the armed forces) and 
recommended for several risk groups (including pregnant women, prisoners, 
50 
people with hepatitis, tuberculosis, sexually transmitted diseases, and a history 
of injection drug use or engagement in risky sexual behaviors) (Rüütel et al. 
2011), screening only these target groups would not suffice. Recent local guide-
lines also recommended routine HIV screening for all outpatients aged 16–49 in 
healthcare facilities in regions most affected by HIV in Estonia (EMSA 2012), 
yet a 2014 HIV treatment and care evaluation by WHO uncovered that health-
care providers in Estonia were experiencing challenges in following these guide-
lines due to lack of training and support (WHO Regional Office for Europe 
2014). In Estonia, in addition to enhancing routine HIV testing, more emphasis 
on groups most at risk of acquiring HIV could also facilitate earlier diagnosis 
(WHO 2014a), as a recent study among PWID, the key HIV risk population in 
Estonia, revealed that only a third of supposedly HIV-negative respondents had 
taken a HIV-test in the past year (Vorobjov et al. 2015). Thus, focusing on the 
recently introduced option of HIV testing in settings frequently attended by 
PWID (i.e., needle and syringe exhange sites), could augment HIV testing among 
PWID in Estonia. Also new testing options (e.g., HIV self-testing) could be 
considered in addition to the existing practices in Estonia (UNAIDS 2015b). 
Our research also revealed that in Estonia 58% of PLHIV who had accessed 
HIV medical care at least once after being diagnosed with HIV, were not retained 
in care in 2013. In absolute terms i.e., based on the number of PLHIV “lost” 
between any two steps in the care cascade, retention was the biggest issue in 
HIV care in Estonia in 2013. However, unlike the relatively “strict” definition for 
‘retained in care’, applied in our study (Ford & Spicer 2012), Europe (ECDC) 
seems to be heading towards a more “permissive” approach in monitoring PLHIV 
retention in HIV care – considering at least one medical care visit per year (in 
consecutive years) sufficient for PLHIV to be defined as ‘retained in care’ (WHO 
2014b, ECDC 2015c). Altogether, we believe that getting tested/diagnosed was 
the main issue in HIV care in Estonia in 2013. Also, the 2015 recommendation 
to prescribe ART to all PLHIV upon diagnosis, introduced by all major 
international HIV treatment guidelines by the end of the year (DHHS 2015, 
EACS 2015, IAPAC 2015, WHO 2015a) should rapidly scale up ART 
distribution, and thus retention as an independent step in the HIV care cascade 
will likely lose value. In our study, had we considered all PLHIV on ART 
(according to our Ministry of Social Affairs, the coordinator of ART in Estonia) 
“automatically” also ‘retained in care’, the public health significance of the 
retention issue in Estonia would have also decreased remarkably.  
 
We acknowledge several limitations of the HIV care cascade analysis. First, as 
the true number of people infected with HIV in Estonia is not known, the 
UNAIDS Spectrum estimate was applied (AIDSinfo 2014). However, the esti-
mates for the following steps in the HIV care cascade are very sensitive to the 
HIV prevalence estimate. Secondly, the different sources of data about PLHIV 
and services provided to them were established at different times, for different 
purposes, by different institutions. Data availability was the main obstacle to 
mapping HIV care, as also recognized by other researchers (Haber et al. 2016). 
51 
Although we applied carefully constructed case-finding algorithms to identify 
HIV-positive individuals from all the health administrative databases, some cases 
may have been misclassified. However, we believe that the nationwide coverage 
of the Estonian Health Insurance Fund (EHIF), and the Estonian Health Board 
(EHB) strengthen our analysis. In particular, we considered EHIF data (used to 
derive population based estimates on medical care linkage, retention and ART 
coverage) relatively complete, as EHIF reimburses healthcare providers on a 
fee-for-service basis. However, none of the databases included all the infor-
mation needed to characterize PLHIV at all the steps of HIV care in Estonia, and 
therefore several assumptions, and data extrapolation from one database to 
another (to obtain a population-based estimate) had to be made. While these 
limitations were important, we feel it is extremely unlikely that they created the 
patterns that we observed in the data. 
 
 
6.2. Antiretroviral therapy adherence and factors 
associated with it among HIV-positive adults  
receiving HIV medical care in Estonia 
The proportion of people virally suppressed among all people living with HIV is 
often viewed as the main indicator for the success of HIV care. While combined 
ART enables to achieve viral suppression, only adhering to the therapy enables 
to maintain it. 
In our study vast majority of PLHIV (88%, 95% CI 81–92%) self-reported 
100% ART adherence in past 3 days. This high rate was in line with findings 
from studies in other countries, with self-reported adherence among vulnerable 
populations (including people using drugs) ranging from 84–97% (Walsh & 
Sherr 2002, Giordano et al. 2004, Oyugi et al. 2004, Amico et al. 2005). It has 
been suggested that by self-report patients tend to overestimate adherence 
(Chesney et al. 2000), also likely in our study mostly due to social desirability 
bias. Despite the efforts to minimize the bias, we still suspect some adherence 
over-reporting in our study, as 40% of “perfect adherers” by self-report were 
not virally suppressed.  
Although the cross-sectional data did not allow causal analysis, we were 
able to study ART adherence association with several potential adherence 
determinants. We found that general health status, measured as self-rated health, 
was a correlate to ART nonadherence. Participants rating their health less than 
good were more likely to be nonadherent. However, the few previous studies 
that have assessed this association, have derived conflicting results on whether 
lower self-rated health is a risk factor for (Cardarelli et al. 2008) or protective 
against (Christofides et al. 2006) nonadherence. In our study nonadherence was 
also associated with higher ART concerns, in line with previous studies where 
nonadherence has been linked to concerns about medication side effects (Johnson 
et al. 2011, Langebeek et al. 2014) and long-term toxicities, scheduling demands 
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and personal capacity to adhere, concerns about the impact of ART on self-
identity, and the possibility that taking treatment might lead to disclosure of the 
one’s HIV status (Gonzales et al. 2007, Langebeek et al. 2014).  
In our study we found no relation between ART adherence and drug use, 
consistent with growing international evidence (Carrieri et al. 2003, Malta et al. 
2010, Walsh et al. 2014). In the context of the Estonian mainly IDU-driven HIV 
epidemic this finding hopefully helps to refute the myth that drug-users are less 
likely to adhere to ART (Beyrer et al. 2010), and affects positively the treatment 
decisions made by HIV medical care providers in Estonia.  
In the same cohort of patients at Ida-Viru Central hospital, among the 75 
individuals who had been randomized to the intervention arm in the RCT 
evaluating the ART adherence support intervention developed for Estonia, 
medication side-effects as a barrier to adherence were also brought up most 
frequently by the patients (44%) in the first intervention counseling session. 
Our study participants, PLHIV treated at Ida-Viru Central Hospital, serving 
about 1/5 of PLHIV in care in Estonia at the time of the study, did not differ 
significantly from HIV-positive patients in care in Estonia in general, except to 
some extent with regards to age, and the profile of HIV disease diagnoses 
(EHIF 2011). However, using the nonprobability sample may have limited the 
representativeness and generalizability of our findings. Due to the small study 
sample size, with the relatively small proportion of participants reporting non-
perfect adherence, some of our measures of association may have lacked sta-
tistical significance simply due to insufficient power or data cell sparsity. While 
appropriate statistical methods were adopted to account for the low cell counts, 
generalizability to larger populations of nonadherent individuals, who may only 
infrequently attend the clinic, was clearly limited.  
 
 
6.3. A feasible evidence-based antiretroviral therapy 
adherence support program tailored to HIV-positive  
adults receiving HIV medical care in Estonia 
The importance of building an intervention on both theory and empirical evidence 
has been well recognized (Bartholomew et al. 2006, Craig et al. 2008). We 
followed Intervention Mapping (IM) as a framework to keep the program 
objectives and activities grounded on both theory and evidence, and not to lose 
focus of both the target population and the program development process (Kok 
et al. 2004). From start, we also recognized the importance of having a multi-
disciplinary team (WHO 2003, Bartholomew et al. 2006, Rueda et al. 2006), as 
no single specialist would have possessed expertise to cover all the methodo-
logical and practical issues of the complex topic of ART adherence within the 
local environment and medical care system.  
One prerequisite for developing any intervention is assessing the need(s) of 
the target population – in our case, PLHIV in HIV care and on ART in Estonia. 
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Although the issue of low treatment adherence was first recognized by service 
providers, focus group interviews were essential to understand the patient per-
spective of adhering to HIV treatment.  
Our research program began with what we identified as a minimum intensity 
intervention with high generalizability due to low use of resources, as we were 
most interested in identifying promising interventions with immediate application 
to our clinical care environments.The theoretical basis for our program i.e., the 
Intervention-Motivation-Behavioral Skills model of adherence, and all the 
strategies applied had either been tested in other ART adherence interventions 
(Sabin et al. 2010) or recommended by professional organizations or other 
researchers (APA 1997, Simoni et al. 2003, Jani 2004, Rueda et al. 2006, 
Chesney 2015). Although several intervention approaches were reviewed and 
other(s) could have been adapted to our setting, Next Step Counseling was 
selected due to flexibility and focus on facilitators to and experiences with 
adherence (versus focusing on barriers). The feasibility, acceptability, and 
fidelity of the intervention were evaluated alongside with the intervention effect 
(compared to standard adherence support in the RCT) outside the scope of this 
work. However, in initial spontaneous feedback from the study site the clinic 
personnel did not complain about excessive intervention-related work load, but 
reported better understanding of their patients through enhanced commu-
nication. The nurse counselors also reported feeling rewarded by the “Aha!” 




6.4. Systematically indentified and synthesized evidence 
for supporting safe sexual behavior among HIV-positive 
adults receiving HIV medical care in Estonia 
We conducted a meticulous search for research published since the era of HIV 
began in 1981, with terms addressing all the main concepts of our review 
question, and feel confident that located all the available studies. However, only 
5 studies of behavioral interventions for adult PLHIV that were provided on 
individual level by caregivers in HIV care settings and promoted safe sexual 
behavior, met our review criteria (The Healthy Living Project Team 2007, 
Cornman et al. 2008, Gilbert et al. 2008, Safren et al. 2013, Kurth et al. 2014). 
The small number of intervention trials focusing on PLHIV was unexpected, 
though in line with findings from a previous review (Johnson et al. 2006). 
Although RCTs provide the strongest evidence regarding the efficacy of HIV 
risk-reduction interventions, we admit that including studies with other mini-
mally biased methods of assigning participants to study arms may have added 
valuable evidence. We also excluded many studies from our review because of 
group-level interventions or using peer(s) as intervention provider(s), as requiring 
patients to attend extra sessions at the clinic (for pre-scheduled group meetings) 
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or additional human resources (peers present during clinic opening hours). 
Choosing individual level interventions was justified by the need to fit the 
intervention into busy HIV clinic situations during routine interactions with 
patients, potentially combining the sexual behavior intervention with the ART 
adherence intervention developed for Estonia. However, in HIV clinics with 
more and different specialty care providers (including peer counselors) available, 
more diverse interventions could better meet the needs of PLHIV.  
Our ability to draw conclusions was further limited by the quality of evid-
ence. Although currently 3 of the 5 studies included in our review (The Healthy 
Living Project Team 2007, Gilbert et al. 2008, Kurth et al. 2014) have been 
considered ‘best evidence’ by the CDC’s HIV/AIDS Prevention Research Syn-
thesis Project (CDC 2016b), we had several concerns about the risk of bias in 2 
of these studies (The Healthy Living Project Team 2007, Gilbert et al. 2008). 
This discrepancy likely derives from a more rigorous risk of bias evaluation in 
our study, following the Cochrane systematic review methodology (Higgins & 
Green 2011). 
Although we looked at one outcome – sexual risk behavior reduction, we 
allowed multiple measures from one study, thus maybe “diluting” the inter-
vention effect to some extent. Also definitions for the outcome measures varied 
across the studies, e.g., a HIV transmission risk act was defined either as a sexual 
act with a serodiscordant partner when a condom was not used, or an act when a 
condom was either not used or used with a problem/error, despite the latter 
perhaps suggesting low condom use skills rather than willingness to use a 
condom. 
To support safe sexual behavior among PLHIV, we found evidence on the 
intervention reducing the number of (casual) sexual partners in one study with 
relatively low quality (Gilbert et al. 2008). Regarding condom use consistency, 
results from two studies (Safren et al. 2013, Kurth et al. 2014) were contra-
dictory, yet good quality evidence from one of the studies (Kurth et al. 2014) 
suggested that an individual behavioral intervention aimed at sexual risk reduc-
tion is likely to increase safe practices. The complex nature of the dichotomous 
‘always/not always using a condom’ measure (i.e., condom use consistency) 
might have affected the “negative” result of the other study (Safren et al. 2013), 
as PLHIV in the intervention group having never or seldom used a condom 
prior to the study might have started to use condoms sometimes, but not in 
100% of sexual acts and were thus still considered not consistently using 
condoms at follow-up, despite the potentially “positive” effect of the inter-
vention and sexual risk behavior reduction among study participants in the 
intervention group. Although in one of the studies (The Healthy Living Project 
Team 2007) the intervention effect did not last till study end, interim analysis at 
study months 15 and 20 deducted reduction in the number of sexual trans-
mission risk acts (i.e., acts with a partner with HIV-negative or unknown sero-
status). It is important to note that the other 4 studies had only run for 6–12 
months. Still, the intensity of the Healthy Living Project intervention (15 
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sessions a year, 90 minutes each) is likely to limit the applicability of this inter-
vention in busy HIV clinic situations.  
Two of the three interventions found to reduce sexual risk behavior among 
PLHIV in our review (Gilbert et al. 2008, Kurth et al. 2014) could be con-
sidered for adaptation in Estonia. Although both the interventions were multi-
topic, the issues addressed in addition to sexual risk behavior would also be 
relevant in Estonia – ART adherence (Kurth et al. 2014), and illicit drug-use and 
alcohol consumption (Gilbert et al. 2008). Despite that both the interventions 
were computerized, this should not limit their application in HIV medical care 
settings in Estonia.  
Although we were not overwhelmed with good quality evidence, we still 
strongly believe that regular interactions between care providers and PLHIV in 
HIV care setting provide valuable opportunities for evidence-based sexual risk 
reduction interventions (Flickinger et al. 2013), as also recognized in the United 
States, were HIV care providers are advised to take any opportunity for brief 
HIV-related risk behavior reduction interventions whenever a patient with HIV 
visits (CDC et al. 2003).  
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7. CONCLUSIONS 
1. In Estonia, in 2013 people living with HIV (PLIHV) were “lost” to care at 
each step of the HIV care cascade, and only 12% (10–15%) of all the 8 628 
(6 941–10 783) HIV-positive people estimated to live in Estonia had 
achieved viral suppression. The main gaps in HIV care in 2013 were that 
about a quarter of PLHIV had not been diagnosed with HIV, and over half 
of PLHIV who had accessed HIV medical care from an infectious disease 
specialist after diagnosis, were not retained in care. With HIV testing 
(including late testing) as the primary bottleneck in HIV care in Estonia, in 
addition to enhancing routine HIV testing (including the current counseling 
and referral to care procedures and practices), more emphasis on groups 
most at risk of acquiring HIV and key settings could facilitate (earlier) 
testing for HIV. 
2.  In Estonia, adult PLHIV receiving HIV care including antiretroviral therapy 
(ART) in an area with high prevalence of injection drug use, self-reported 
ART adherence rates were high despite low viral suppression. Adherence 
was most strongly associated with perceived health status and beliefs about 
the consequences of ART. Nonadherence was not differentially higher 
among people who inject drugs. Adherence support programs or approaches 
may be most effective if they target beliefs about ART necessity and effi-
cacy, concerns about side effects and long-term toxicities. 
3.  A feasible evidence-based ART adherence support intervention was devel-
oped, tailored to the needs of HIV-positive adults in HIV medical care in 
Estonia, transferable to all medical institutions providing HIV/AIDS care in 
Estonia and potentially abroad to other countries with similar socio-eco-
nomic history and HIV epidemic evolution. The intervention would fit into 
the daily routine of a clinic as could be performed in a relatively short 
amount of time and thus added to other routine interactions with patients in 
the clinic, would reach the patients when they attend the clinic and not 
require additional visits, and would not (in most part) require extra staff.  
4.  Research on behavioral interventions supporting safe sexual behavior among 
adult PLHIV in HIV care was systematically searched and synthesized. 
Two interventions, provided on individual level by caregivers in HIV care 
settings and applicable to the local epidemiological and healthcare context in 
Estonia, and potentially in other countries with similar socio-economic and 
HIV epidemiologic history, were identified. One of the interventions resulted 
in significant increase in condom use consistency in HIV transmission risk 
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SUMMARY IN ESTONIAN 
HIV-positiivsed inimesed Eestis: hõlmatus raviteenustega  
ning antiretroviirusravi soostumust ja turvalist  
seksuaalkäitumist toetavad sekkumised 
2014. aastal elas maailmas hinnanguliselt ligi 37 miljonit HIVi nakatunud ini-
mest, samas oli HIVi-epideemia tõttu ligi nelja kümnendi jooksul surnud üle 39 
miljoni inimese (UNAIDS 2014a, UNAIDS 2015a). Tänapäeval on olemas 
tõhus HIV-infektsiooni vastane ravi – kombineeritud antiretroviirusravi (ARV-
ravi) – ning tänu sellele on HIV-infektsioon muutunud ägedast haigusest krooni-
liseks. 2015. aastal sai maailmas kõigist HIVi nakatunud inimestest ARV-ravi 
hinnanguliselt ligi 15,8 miljonit (UNAIDS 2015a, UNAIDS 2015b) ning kokku 
oli ARV-ravi käesoleval aastatuhandel päästnud ligi 7,8 miljoni inimese elu 
(Fauci & Marston 2015). ARV-ravi ei ole elulise tähtsusega mitte üksnes juba 
HIVi nakatunud inimesele, vaid see vähendab olulisel määral ka viiruse üle-
kande tõenäosust teistele (Altice jt 2001, WHO 2003, Mannheimer jt 2005, 
Chesney 2006, Ray jt 2010, Cohen jt 2011, WHO 2015a). Et ARV-ravi viirust 
lõplikult ei hävita (Lorenzo-Redondo jt 2016), ei ole HIVi leviku tõkestamisel 
vähenenud ka HIV-positiivsete inimeste turvalise seksuaalkäitumise olulisus 
(Kennedy jt 2010, Mermin 2011, Lasry jt 2012). Viimasel ajal on HIVi-vastases 
võitluses nihkunud fookus HIV-negatiivsetelt inimestelt HIV-positiivsetele, sest 
rahvatervishoiu vaatevinklist on epideemia tõkestamiseks tõhusam keskenduda 
pigem suhteliselt väiksemale HIVi nakatunud kui suuremale mitte veel naka-
tunud osale rahvastikust (Kennedy jt 2010, Mermin 2011, Lasry jt 2012). Ühi-
nenud Rahvaste Organisatsiooni HIVi-AIDSi ühendprogrammis (UNAIDS) 
seati 2014. aastal HIVi-vastasele võitlusele uued ambitsioonikad eesmärgid: 
90% HIVi nakatunud inimestest peaks olema oma (sero)staatusest teadlikud ehk 
saanud HIVi diagnoosi, 90% HIVi diagnoosiga inimestest peaks saama ARV-ravi 
ning 90% ravisaajaist peaks olema saavutanud HI-viiruse üle kontrolli ehk viirus-
supressiooni. UNAIDSi prognoos näitab, et kui need eesmärgid suudetakse 2020. 
aastaks täita, on võimalik maailmas 2030. aastaks HIVi-epideemiale piir panna 
(UNAIDS 2014b, UNAIDS 2014c).  
Tänapäeval peaks inimene HIVi nakatumise järel sujuvalt asjakohaste ravi-
teenusteni jõudma ning mõne aja möödudes HIVi üle kontrolli saavutama. 
Rahvusvahelised uuringud on aga näidanud, et märgatav osa HIV-positiivseid 
inimesi langeb sellest (ravi)protsessist (ingl continuum) eri ajal ning erinevatel 
põhjustel välja. Viimastel aastatel on HIVi-vastase võitluse tulemuslikkuse hinda-
misel järjest enam kasutatud Ameerika Ühendriikides 2011. aastal E. Gardneri 
ja kolleegide väljatöötatud HIVi raviastmestiku mudelit (Gardner jt 2011), et 
mõõta HIV-positiivsete inimeste hõlmatust HIVi raviteenustega selle mudeli eri 
astmetel (Helleberg jt 2013, Pokrovskaya jt 2014, Raymond jt 2014, Levi jt 2015, 
Medland jt 2015). Nii on lisaks ravile ning laiemalt kõigi HIVi korral näidus-
tatud tervishoiuteenuste olemasolule vaja tagada neile ka juurdepääs ning igati 
toetada nende teenuste kasutamist (Nosyk jt 2014). Näiteks tuleb ARV-ravimeid 
71 
võtta elu lõpuni iga päev mitu korda. Aja jooksul võib see HIV-positiivsele ini-
mesele parimagi teadlikkuse ja tahtmise korral osutuda väljakutseks, mistõttu 
on välja töötatud ravisoostumust toetavad meetodid ja sekkumised. Neist opti-
maalse valimine eeldab aga head ülevaadet nii kohalikest oludest kui ka HIV-
positiivsete inimeste vajadustest.  
Kuigi Eestis on esmashaigestumus HIVi alates 2006. aastast pidevalt vähe-
nenud, oli Eesti 2014. aastal Euroopa Liidus ning Euroopa Majanduspiirkonnas 
22,1 esmaselt registreeritud HIVi-juhuga 100 000 inimese kohta jätkuvalt esi-
kohal (ECDC/WHO Regional Office for Europe 2015). HIVi ravi (sh ARV-
ravi) on Eestis kõigile seda vajavatele HIV-positiivsetele inimestele tervise-
kindlustuse olemasolust sõltumata kättesaadav ja tasuta (Laisaar jt 2011, IV 
publikatsioon).  
 
Doktoritöö üldeesmärk oli kirjeldada HIV-positiivsete inimeste kaasatust HIVi 
ravisse (sh soostumust ARV-raviga) Eestis ning töötada välja täiskasvanud 
HIV-positiivsetele ARV-ravil olevatele inimestele ravisoostumust ja turvalist 
seksuaalkäitumist toetavad sekkumised.  
 
Uurimistöö alaeesmärgid: 
1) kirjeldada ja hinnata Eestis elavate HIV-positiivsete inimeste hõlmatust 
asjakohaste tervishoiuteenustega (sh ARV-raviga) ning teha kindlaks pea-
mised lüngad tervishoiuteenuste osutamisel, et aidata kaasa süsteemi 
parendamisele (IV publikatsioon); 
2) kirjeldada ja hinnata Eestis ARV-ravi saavate HIV-positiivsete täiskasva-
nute ravisoostumust ja sellega seotud tegureid (I ja II publikatsioon);  
3) töötada välja Eestis elavate HIV-positiivsete ARV-ravi saavate ja alustavate 
täiskasvanute vajadustele vastav ning ravisüsteemi võimalusi arvestav tõen-
duspõhine ravisoostumust toetav sekkumine, mis oleks rakendatav ka teis-
tes sarnase HIVi-epideemia ning sotsiaalmajandusliku taustaga riikides 
(I publikatsioon);  
4) töötada süstemaatiliselt läbi uuringud, mis on keskendunud ravi saavate HIV-
positiivsete täiskasvanute turvalist seksuaalkäitumist toetavatele ravitee-
nuste osutajate poolt individuaalselt rakendatud sekkumistele; võtta need tule-
mused kokku, et valida välja tõhusad sekkumised, mis sobiksid kasutamiseks 
Eesti raviasutustes ning tõenäoliselt ka teistes sarnase HIVi-epideemia ning 




Uurimistööd juhtis Tartu Ülikooli peremeditsiini ja rahvatervishoiu instituudi 
HIVi-AIDSi teadusrühm. Uurimistöö algas 2010. aastal Eesti HIVi-epideemia 
ning riiklike ja muude eelneva kümnendi (2000–2009) jooksul rakendatud 
vastumeetmete (HIVi-testimisest ARV-ravini) väljaselgitamisega ning Eesti ja 
teiste Ida-Euroopa riikide olukorra võrdlemisega. Selle töö tulemusi (Laisaar jt 
2011) on kasutatud käesoleva uurimistöö kirjanduse ülevaates.  
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Tõenduspõhise ja Eestis HIVi ravi saavate täiskasvanute vajadustele ning 
tervishoiusüsteemi võimalustele kohandatud ARV-ravi soostumust toetav 
sekkumine töötati välja aastail 2010–2011 korraldatud uuringu käigus, tuginedes 
sekkumisraamistikule (ingl Intervention Mapping, IM) (Bartholomew jt 2006, 
Kok jt 2004), kombineerides kvalitatiivseid ja kvantitatiivseid andmete kogu-
mise ja sünteesi meetodeid. IM-protokoll koosnes kuuest astmest: 1) sihtrühma 
(täiskasvanud HIV-positiivsed ARV-ravi saajad Eestis) vajaduste väljaselgita-
mine, 2) sekkumisprogrammile (lõpp)eesmärkide seadmine, 3) sobivate meeto-
dite (teooriate) ja rakenduste valimine, 4) sekkumise (kitsamas mõttes) välja-
töötamine, 5) sekkumisprogrammi rakendusplaani koostamine ja programmi ellu-
viimine, 6) sekkumisprogrammi hindamine. Kõigil IM-raamistiku etappidel 
kasutasime järgmisi andmekäitluse meetodeid: elektroonilises inforuumis kätte-
saadava kirjanduse ülevaate koostamine; ARV-ravi soostumusest arusaamade ja 
ARV-ravi soostumuse mõjurite väljaselgitamine (intervjuud ravi saanud HIV-
positiivsete inimestega ja raviteenuse pakkujatega Ida-Viru maakonnas); kogutud 
andmete analüüs multidistsiplinaarse uuringumeeskonna arutelude (kohtumiste 
ja telekonverentside) käigus ning individuaalselt. (I publikatsioon) 
ARV-ravi soostumuse määra ning sellega seotud tegurite kohta Eestis saadi 
andmed läbilõikelisest uuringust, mis korraldati 2010. aastal Ida-Viru Keskhaiglas 
ARV-ravi saajate seas. Uuritavate ravisoostumust mõõdeti nende endi hinnangul 
viimase kolme päeva jooksul võtmata jäänud ravimiannuste alusel (Chesney jt 
2000). Statistilises analüüsis oli peamiseks tulemiks raviga mittesoostumine: 
uuritav arvati mittesoostujaks, kui ta ei olnud võtnud kõiki ravimiannuseid õigel 
ajal. Standardiseeritud küsimustiku alusel korraldatud küsitluse käigus koguti 
uuritavate sotsiaaldemograafilised, HIV-infektsiooni ja ravikogemuse, narkooti-
kumide tarvitamise jm andmed, mida võrreldi raviga soostujate ja mittesoostu-
jate rühmas. Uuriti erinevate tunnuste seost ravisoostumusega, arvutati kohan-
damata mittesoostumise šansisuhted. Seejärel kohandati šansisuhted tunnustele, 
mis olid kohandamata analüüsis osutunud mittesoostumisega statistiliselt olu-
lisel määral seotuks ning mida ei saanud pidada ravisoostumuse tulemiks. (II 
publikatsioon) 
Ravisoostumust soodustavate ja takistavate tegurite kohta saadi andmed 
sekkumisrühma uuritavate nõustamissessioonide ajal toimunud osaliselt struktu-
reeritud (nõustaja poolt uuritavate sõnade kohaselt kirja pandud) vestlustest, mis 
peeti juhuslikustatud kontrollitud uuringu käigus, mis korraldati Eestis välja-
töötatud ravisoostumust toetava sekkumise (kirjeldatud eespool) hindamiseks. 
(I publikatsioon)  
Potentsiaalselt Eesti oludesse sobiva HIV-positiivsete inimeste turvalist sek-
suaalkäitumist toetava efektiivse sekkumise väljaselgitamiseks koostati 2014. 
aastal teaduskirjanduse süstemaatiline ülevaade. Publikatsioonide otsimiseks 
elektroonsetest andmebaasidest koostati uuringuküsimuse alusel otsinguterminite 
nn puu, mis sisaldas järgmisi üldmõisteid: HIV/AIDS, seksuaalne (riski)käitu-
mine, käitumuslik sekkumine, (kvaasi)randomiseeritud uuringukavand. Ajaliselt 
vaadati publikatsioone aastatest 1981 kuni 2013 (k.a). Lisaks vaadati läbi 
Cochrane Collaboration’i HIVi-AIDSi töörühma soovitatud HIVi-AIDSi vald-
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konna samal ajavahemikul toimunud teaduskonverentside teesid. Süstemaatilise 
ülevaate koostamisel järgiti Cochrane Collaboration’i metoodikat (Higgins & 
Green 2011). Ülevaatesse kaasati (kvaasi)randomiseeritud kontrollitud uuringud, 
milles oli uuritud HIV-positiivsete HIVi ravi saavate inimeste seas individuaalselt 
raviteenuse osutaja(te) läbiviidud seksuaalset riskikäitumist mõjutavate sekku-
miste mõju võrreldes mittesekkumisega. Tulemiks oli seksuaalse riskikäitumise 
vähenemine, mida mõõdeti partnerite arvu, kondoomita vahekordade arvu ja/või 
kondoomi kasutamise järjekindluse muutuse ja/või seksuaalsel teel levivasse 
infektsiooni, B-hepatiiti haigestumise alusel. Et huvi pakkusid pikemaaegse 
mõjuga sekkumised, kaasati ülevaatesse vaid need uuringud, kus sekkumise mõju 
oli hinnatud mitte varem kui 90 päeva pärast sekkumistegevuse algust. Üle-
vaatesse kaasatud uuringute tulemusi analüüsiti kvalitatiivselt. (III publikatsioon) 
Eestis elavate HIV-positiivsete inimeste raviteenustega hõlmatuse hindami-
seks tehti aastail 2014–2015 läbilõikeline analüüs, mis tugines HIV-positiivsete 
inimeste andmeid sisaldavatele riiklikele ja muudele olemasolevatele rahvastiku-
põhistele andmebaasidele. Analüüsi aluseks võeti UNAIDSi hinnanguline Eestis 
elavate HIV-positiivsete inimeste arv ning tugineti Ameerika Ühendriikides 
riiklikult kasutatavale metoodikale (CDC 2011, Ford & Spicer 2012). 2013. aasta 
seisuga hinnati järgmisi HIVi raviastmestiku näitajaid ehk inimeste arvu (ning 
alates teisest astmest ka osakaalu kõigist HIVi nakatunuist), kes olid 1) HIVi 
nakatunud, 2) saanud HIVi diagnoosi, 3) jõudnud HIVi ravile ja/või jälgimisele 
nakkushaiguste arsti juurde, 4) said püsivalt HIVi ravi või olid jälgimisel, 5) said 




Peamised tulemused ja arutelu 
Uurimistöö käigus töötati välja Eestis HIVi ravi saavate täiskasvanute vaja-
dustele ning tervishoiusüsteemi võimalustele kohandatud ARV-ravi soostumust 
toetav tõenduspõhine sekkumine nimetusega Situated Optimal Adherence Inter-
vention (sOIA) Estonia. Tuginedes intervjuudest selgunud vajadusele parandada 
patsientide arusaamu ARV-ravimite toimest ning ravisoostumusest, töötati välja 
3-seansiline nõustamine, mis tugineb ravisoostumusega seotud teavitamise-moti-
veerimise-käitumisoskuste (ingl Information–Motivation–Behavioral Skills, IMB) 
teooriale (Fisher jt 2006 Munro jt 2007, Fisher jt 2008) ja rajaneb nõustamis-
metoodikal Next Step Counseling (Amico jt 2010, Grant jt 2010) ning mille 
rakendamine lisati patsientide tavapärastele, muu hulgas ravimivaru täiendamise 
visiitidele haigla nakkushaiguste osakonda. Ehkki selle sekkumise mõju hinda-
miseks korraldatud juhuslikustatud kontrollitud uuring jääb käesoleva uurimistöö 
piiridest välja, selgus juba esimeste nõustamisseansside järel, et nõustamine 
sobitus haigla tihedasse töörütmi, selleks ei olnud vaja lisapersonali, ning nõus-
tajad (õed) tunnistasid, et nad hakkasid oma patsiente parema suhtluse tulemusena 
enam mõistma ning et nad rõõmustasid ahhaa-efekti üle, mida patsiendid 
nõustamise käigus jagatud teabe tulemusena kogesid. 
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ARV-ravi saavate HIV-positiivsete täiskasvanute ravisoostumuse uurimisel 
selgus, et suurem osa (144st uuritust 88%) hindas oma ravisoostumust heaks, 
samas objektiivselt ehk HIV RNA analüüsi tulemuste põhjal oli haigus tege-
likult kontrolli all ehk HIV supresseeritud neist vähem kui pooltel (40%-l). See 
tulemus viitab patsientide võimalikule enese ravisoostumuse ülehindamisele, tõe-
näoliselt eelkõige tänu soovile end tervishoiutöötajatele meelepärasemas valguses 
näidata. Kõige enam osutus ravisoostumus seotuks uuritute ARV-ravi ja ravi 
võimalikke mõjusid puudutavate uskumustega, samuti enesehinnangulise tervise-
seisundiga. Ka ravisoostumust toetava sekkumise mõju hindamiseks korraldatud 
juhuslikustatud kontrollitud uuringu esmavisiidil nimetati sekkumisrühmas ravi-
soostumuse tõkkena kõige sagedamini ARV-ravimite võimalikke kõrvaltoimeid 
(75st uuritust 44%). Mõlema uuringu tulemused viitavad sellele, et ARV-ravi 
soostumust toetavate sekkumiste puhul peaks keskenduma ARV-ravimite toime 
(sh kõrvaltoimete) selgitamisele. 
Ravisoostumuse määra ja mõjurite uuring näitas veel, et süstivate narko-
maanide (SNide) seas ei olnud ARV-raviga mittesoostujaid oluliselt rohkem kui 
mitte-SNide seas. See tulemus on kooskõlas mitmete mujal maailmas tehtud 
uuringute tulemustega (Carrieri jt 2003, Malta jt 2010, Walsh jt 2014) ning aitab 
loodetavasti Eesti süstitavate narkootikumide sõltuvusega seotud HIVi-epi-
deemia kontekstis kummutada müüte SNide halvemast ravisoostumusest ning 
kõrvalda tervishoiutöötajate kõhklusi SNide ravimise otsuste tegemisel. 
 
Süstemaatilises ülevaates, milles keskenduti HIV-positiivsete ravi saavate 
inimeste turvalist seksuaalkäitumist toetavatele sekkumistele, vastas uuringusse 
kaasamise kriteeriumitele vaid viis teaduslikku uuringut (The Healthy Living 
Project Team 2007, Cornman jt 2008, Gilbert jt 2008, Safren jt 2013, Kurth jt 
2014). Neist vaid kahes olid uuritud sekkumised positiivse mõjuga: ühes uurin-
gus vähenes sekkumise tulemusel uuringus osalenute juhuslike seksuaalpart-
nerite arv (Gilbert jt 2008) ning teises paranes HIV-positiivsete inimeste kon-
doomikasutuse järjekindlus seksuaalvahekordades, kus teine osapool oli kas 
HIV-negatiivne või teadmata HIVi-staatusega (Kurth jt 2014). Sobiva tõendus-
materjali hulka vähendasid nii küllaltki ranged uuringute ülevaatesse valimise 
tingimused kui ka sõelale jäänud uuringute metoodilised puudused. Sellele 
vaatamata tekkis uuringu tulemusel veendumus, et HIV-positiivsete patsientide 
ja tervishoiuteenuste pakkujate regulaarsed kokkupuuted raviasutuses on heaks 
võimaluseks selgitada patsientidele turvalise seksuaalkäitumise olulisust ning 
seda toetada. 
 
Eesti HIV-positiivsete inimeste raviteenustega hõlmatuse hindamisel selgus, et 
2013. aastal oli 8628-st (6941–10 783) hinnanguliselt Eestis elanud HIVi 
nakatunust (AIDSinfo 2014) HIV-infektsioon diagnoositud 72%-l (47–100%-l). 
Vähemalt ühe visiidi nakkushaiguste arsti juurde oli teinud 51% (41–63%) ning 
püsivalt oli ravil ja/või jälgimisel 21% (17–27%) HIV-positiivsetest inimestest. 
Kuigi ARV-ravi sai 18% (14–22%), oli viirus supresseeritud vaid 12%-l (10–
15%-l) kõigist 2013. aastal Eestis elanud HIV-positiivsetest inimestest. Olulisi-
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maks kitsaskohaks HIV-positiivsete inimeste HI-viiruse kontrolli alla saamisel 
ehk hea ravitulemuseni jõudmisel osutus HIVi diagnoosimine, mis on võimalik 




1. 2013. aastal jäi Eestis HIVi raviteenuste igal astmel mingi osa HIV-posi-
tiivseid inimesi asjakohastest teenustest kõrvale ning üksnes 12% (10–15%) 
kõigist 8628-st (6941–10 783) hinnanguliselt Eestis elanud HIV-positiivsest 
inimesest oli saavutanud HIVi üle kontrolli ehk viirussupressiooni. Kokku-
võttes ei olnud ligi veerandil arvatavalt HIVi nakatunuist HIVi diagnoositud – 
neid ei olnud HIVi suhtes testitud ning nad ei olnud oma sero(staatusest) 
teadlikud. Lisaks ei olnud üle poole diagnoosi saanuist ning ka nakkus-
haiguste arsti vaatevälja jõudnuist püsivalt ravil ja/või jälgimisel. Olukorras, 
kus heade ravitulemusteni jõudmisel on esmaseks kitsaskohaks HIV-testi-
mine (sh võimalikult varane testimine), oleks HIV-testimise ning sellele 
järgneva nõustamise ja ravile suunamise kehtiva korra järgimise tõhusta-
misele lisaks vaja senisest enam tähelepanu pöörata testimisele HIVist enim 
ohustatud rahvastikurühmades ning piirkondades.  
2. Eesti piirkonnas, kus süstitavate narkootikumide sõltuvuse levimus on suur, 
hindas suur osa HIV-positiivsetest ARV-ravi saajatest oma ravisoostumust 
heaks, samas kui suurel osal neist ei olnud viirus supresseeritud. Kõige enam 
oli ravisoostumus seotud enesehinnangulise terviseseisundiga ning ARV-
ravi ja selle võimalike (kõrval)mõjudega seotud uskumustega. Süstivate 
narkomaanide seas ei olnud mittesoostujaid oluliselt rohkem kui mitte-
süstivate uimastisõltlaste seas. Eelnevale tuginedes võib arvata, et ravisoostu-
must toetavad sekkumised annaksid paremaid tulemusi, kui nende rakenda-
misel käsitletaks ARV-ravi vajalikkuse ja toime (sh kõrvaltoimete) küsimusi.  
3. Töötati välja Eesti patsientide vajadusi ning ravisüsteemi võimalusi arves-
tav ravisoostumust toetav sekkumine, mis on rakendatav ka teistes ravi-
asutustes peale haigla, kus uuring korraldati, nii Eestis kui tõenäoliselt ka 
teistes sarnase HIVi-epideemia ning sotsiaalmajandusliku taustaga riikides. 
Raviasutuste töökorraldust arvestav sekkumine ei ole ressursimahukas ning 
tänu sellele saab seda rakendada patsientide tavapäraste (ravi)visiitide käigus. 
4. Täiskasvanud HIV-positiivsete ravi saavate inimeste turvalist seksuaal-
käitumist toetavatele sekkumistele keskendunud uuringute süstemaatilise 
ülevaate tulemusena tehti kindlaks kaks tõenduspõhist sekkumist, mida ravi-
teenuse osutaja saab individuaalselt rakendada ja mis sobiksid kasutamiseks 
Eesti raviasutustes, kuid tõenäoliselt ka teistes sarnase HIVi-epideemia ning 
sotsiaalmajandusliku taustaga riikides. Üks neist sekkumistest vähendas 
olulisel määral HIV-positiivsete inimeste juhuslike seksuaalpartnerite arvu 
ning teine suurendas kondoomikasutuse järjekindlust seksuaalvahekordades 
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